Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.4.24.B11 - ADAMTS1 endopeptidase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abscess
Histopathologic and immunohistochemical investigations of abscess fluid cells formed in the palato-gingival area.
Acquired Immunodeficiency Syndrome
Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team.
Histological characterization of regression in acquired immunodeficiency syndrome-related Kaposi's sarcoma.
adamts1 endopeptidase deficiency
Postnatal deficiency of ADAMTS1 ameliorates thoracic aortic aneurysm and dissection in mice.
Adenocarcinoma
A polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma.
A polymorphism in the angiogenesis inhibitor, endostatin, in sporadic colorectal adenocarcinoma.
Co-opted JNK/SAPK signaling in Wnt/beta-catenin-induced tumorigenesis.
Differentially regulated ADAMTS1, 8, 9, and 18 in pancreas adenocarcinoma.
Differentially regulated ADAMTS1, 8, and 18 in gastric adenocarcinoma.
FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial.
Inhibition of expression of vascular endothelial growth factor and its receptors in pulmonary adenocarcinoma cell by TNP-470 in combination with gemcitabine.
PGF2?-F-prostanoid receptor signalling via ADAMTS1 modulates epithelial cell invasion and endothelial cell function in endometrial cancer.
Vascularization is decreased in pulmonary adenocarcinoma expressing brain-specific angiogenesis inhibitor 1 (BAI1).
[Gastrectomy for Bleeding Gastric Cancer During Ramucirumab plus Paclitaxel Therapy-A Case Report].
Adenocarcinoma of Lung
[Effects of suramin in combination with Cisplatin on growth and metastasis of lung adenocarcinoma xenografts in mice.]
Adenoma
ADAMTS1, CRABP1, and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis.
Role of gene expression profiling in defining indeterminate thyroid nodules in addition to BRAF analysis.
Adenomyosis
Effects of angiogenesis inhibitor TNP-470 on the development of uterine adenomyosis in mice.
Alzheimer Disease
Activation of PPARA-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model.
Do antiangiogenic protein fragments have amyloid properties?
Amyloidosis
Do antiangiogenic protein fragments have amyloid properties?
Anemia
[Gastrectomy for Bleeding Gastric Cancer During Ramucirumab plus Paclitaxel Therapy-A Case Report].
Aneurysm
Analysis of in situ and ex vivo vascular endothelial growth factor receptor expression during experimental aortic aneurysm progression.
Aneurysm, Dissecting
A disintegrin and metalloproteinase with thrombospondin motif 1 (ADAMTS1) expression increases in acute aortic dissection.
Assessing Serum Levels of ADAMTS1 and ADAMTS4 as New Biomarkers for Patients with Type A Acute Aortic Dissection.
The Investigation of a Disintegrin and Metalloproteinase with ThromboSpondin Motifs (ADAMTS) 1, 5 and 16 in Thoracic Aortic Aneurysms and Dissections.
Aortic Aneurysm, Thoracic
Postnatal deficiency of ADAMTS1 ameliorates thoracic aortic aneurysm and dissection in mice.
The Investigation of a Disintegrin and Metalloproteinase with ThromboSpondin Motifs (ADAMTS) 1, 5 and 16 in Thoracic Aortic Aneurysms and Dissections.
Aortic Diseases
Nitric oxide mediates aortic disease in mice deficient in the metalloprotease Adamts1 and in a mouse model of Marfan syndrome.
Arthritis
ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro.
Angiogenesis inhibition by the novel VEGF receptor tyrosine kinase inhibitor, PTK787/ZK222584, causes significant anti-arthritic effects in models of rheumatoid arthritis.
Angiogenesis inhibition suppresses collagen arthritis.
Suppression of arthritis and protection from bone destruction by treatment with TNP-470/AGM-1470 in a transgenic mouse model of rheumatoid arthritis.
Therapeutic effects of sunitinib, one of the anti-angiogenetic drugs, in a murine arthritis.
Arthritis, Experimental
A novel angiogenesis inhibitor suppresses rat adjuvant arthritis.
An angiogenesis inhibitor, 2-methoxyestradiol, involutes rat collagen-induced arthritis and suppresses gene expression of synovial vascular endothelial growth factor and basic fibroblast growth factor.
Blockage of the formation of new blood vessels by recombinant human endostatin contributes to the regression of rat adjuvant arthritis.
Involution of collagen-induced arthritis with an angiogenesis inhibitor, PPI-2458.
Modulation of T lymphocyte function by the angiogenesis inhibitor AGM-1470.
Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: reduction of vascular endothelial growth factor (VEGF).
Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, taxol.
Suppression of type II collagen-induced arthritis by ICM0301B, a new angiogenesis inhibitor.
The angiogenesis inhibitor protease-activated kringles 1-5 reduces the severity of murine collagen-induced arthritis.
The effect of endostatin evaluated in an experimental animal model of collagen-induced arthritis.
Therapeutic effects of sunitinib, one of the anti-angiogenetic drugs, in a murine arthritis.
Arthritis, Rheumatoid
Imbalance in production between vascular endothelial growth factor and endostatin in patients with rheumatoid arthritis.
Potent inhibition of angiogenesis by wortmannin, a fungal metabolite.
Pristimerin inhibits angiogenesis in adjuvant-induced arthritic rats by suppressing VEGFR2 signaling pathways.
Tranilast inhibits the proliferation, chemotaxis and tube formation of human microvascular endothelial cells in vitro and angiogenesis in vivo.
Treatment with the angiogenesis inhibitor endostatin: a novel therapy in rheumatoid arthritis.
Asthma
ADAM metallopeptidase domain 33 (ADAM33): a promising target for asthma.
Association between ADAM metallopeptidase domain 33 gene polymorphism and risk of childhood asthma: a meta-analysis.
Genome-wide association study in Spanish identifies ADAM metallopeptidase with thrombospondin type 1 motif, 9 (ADAMTS9), as a novel asthma susceptibility gene.
Vascular endothelial growth factor antagonism restores epithelial barrier dysfunction via affecting zonula occludens proteins.
Astrocytoma
Expression of brain-specific angiogenesis inhibitor 1 is inversely correlated with pathological grade, angiogenesis and peritumoral brain edema in human astrocytomas.
Atherosclerosis
ADAMTS1 interacts with, cleaves, and modifies the extracellular location of the matrix inhibitor tissue factor pathway inhibitor-2.
Angiogenesis Inhibitor, Endostar, Prevents Vasa Vasorum Neovascularization in a Swine Atherosclerosis Model.
Early-onset coronary artery disease after pediatric kidney transplantation: implicating the angiogenesis inhibitor, endostatin.
Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis.
MiR-362-3p inhibits the proliferation and migration of vascular smooth muscle cells in atherosclerosis by targeting ADAMTS1.
Azoospermia
ADAMTS1 and ADAMTS5 metalloproteases produced by Sertoli cells: a potential diagnostic marker in azoospermia.
Blindness
Technology evaluation: SELEX, Gilead Sciences Inc.
[Cytokine aptamers as therapeutic and diagnostic agents]
Bone Resorption
Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption.
Histopathologic and immunohistochemical investigations of abscess fluid cells formed in the palato-gingival area.
Brain Edema
Expression of brain-specific angiogenesis inhibitor 1 is inversely correlated with pathological grade, angiogenesis and peritumoral brain edema in human astrocytomas.
Brain Injuries
Endostatin/Collagen XVIII Is Increased in Cerebrospinal Fluid after Severe Traumatic Brain Injury.
Brain Injuries, Traumatic
Endostatin/Collagen XVIII Is Increased in Cerebrospinal Fluid after Severe Traumatic Brain Injury.
Lesional expression of the endogenous angiogenesis inhibitor endostatin/collagen XVIII following traumatic brain injury (TBI).
Brain Ischemia
Expression of brain-specific angiogenesis inhibitor 3 (BAI3) in normal brain and implications for BAI3 in ischemia-induced brain angiogenesis and malignant glioma.
The quantification of ADAMTS expression in an animal model of cerebral ischemia using real-time PCR.
Brain Neoplasms
Assessment of brain tumor angiogenesis inhibitors using perfusion magnetic resonance imaging: quality and analysis results of a phase I trial.
Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).
Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470.
Breast Neoplasms
Acral cutaneous metastasis from a primary breast carcinoma following chemotherapy with bevacizumab and paclitaxel.
ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis.
ADAMTS1 Promotes Adhesion to Extracellular Matrix Proteins and Predicts Prognosis in Early Stage Breast Cancer Patients.
ADAMTS1-mediated targeting of TSP-1 by PPAR? suppresses migration and invasion of breast cancer cells.
Analysis of a bone metastasis gene expression signature in patients with bone metastasis from solid tumors.
Angiogenesis Inhibitor O-(Chloroacetyl-carbamoyl) fumagillol (TNP-470) Inhibits Tumor Angiogenesis, Growth and Spontaneous Metastasis of MKL-4 Human Breast Cancer Cells in Female Athymic Nude Mice.
Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption.
Angiogenesis inhibitors in the management of breast cancer.
Angiostatin inhibits bone metastasis formation in nude mice through a direct anti-osteoclastic activity.
Breast cancer cells induce stromal fibroblasts to secrete ADAMTS1 for cancer invasion through an epigenetic change.
Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.
Contribution of ADAMTS1 as a tumor suppressor gene in human breast carcinoma. Linking its tumor inhibitory properties to its proteolytic activity on nidogen-1 and nidogen-2.
Current Issues of Targeted Therapy in Metastatic Triple-Negative Breast Cancer.
Effects of angiogenesis inhibitor TNP-470 on tamoxifen-stimulated MCF-7 breast tumors in nude mice.
Endpoints for agents that slow tumor growth.
Human breast adipose tissue: characterization of factors that change during tumor progression in human breast cancer.
Inhibition of tumor growth and metastasis by angiogenesis inhibitor TNP-470 on breast cancer cell lines in vitro and in vivo.
Inhibition of tumor growth by antibody to ADAMTS1 in mouse xenografts of breast cancer.
LncRNA ADAMTS9-AS1 Restrains the Aggressive Traits of Breast Carcinoma Cells via Sponging miR-513a-5p.
Regulation of the angiogenesis inhibitor thrombospondin-1 by the breast cancer susceptibility gene-1 (BRCA1).
Regulation of the Bcas1 and Baiap3 transcripts in the subthalamic nucleus in mice recovering from MPTP toxicity.
Stem-like tumor cells involved in heterogeneous vasculogenesis in breast cancer.
Synergistic action of apoptosis induced by eicosapentaenoic acid and TNP-470 on human breast cancer cells.
Synergistic breast cancer suppression efficacy of doxorubicin by combination with glycyrrhetinic acid as an angiogenesis inhibitor.
The ADAMTS1 protease gene is required for mammary tumor growth and metastasis.
The cleavage of semaphorin 3C induced by ADAMTS1 promotes cell migration.
The effects of hypericin on ADAMTS and p53 gene expression in MCF-7 breast cancer cells.
The in vivo properties of STX243: a potent angiogenesis inhibitor in breast cancer.
Burkitt Lymphoma
The angiogenesis inhibitor vasostatin does not impair wound healing at tumor-inhibiting doses.
Carcinogenesis
ADAMTS1, CRABP1, and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis.
Advances in anti-angiogenic agents for ovarian cancer treatment: The role of trebananib (AMG 386).
An HPLC-ultraviolet detection method for the determination of Z24 in mouse whole blood and its application to pharmacokinetic studies.
An investigation into the potential role of brain angiogenesis inhibitor protein 3 (BAI3) in the tumorigenesis of small-cell carcinoma: a review of the surrounding literature.
Angiogenesis inhibitor TNP-470 suppresses tumorigenesis in rat urinary bladder.
Differentially regulated ADAMTS1, 8, and 18 in gastric adenocarcinoma.
High ADAMTS18 expression is associated with poor prognosis in stomach adenocarcinoma.
Inhibition of tumor growth by antibody to ADAMTS1 in mouse xenografts of breast cancer.
Melatonin-triggered post-transcriptional and post-translational modifications of ADAMTS1 coordinately retard tumorigenesis and metastasis of renal cell carcinoma.
Regulatory roles of brain-specific angiogenesis inhibitor 1(BAI1) protein in inflammation, tumorigenesis and phagocytosis: A brief review.
Stroma-derived but not tumor ADAMTS1 is a main driver of tumor growth and metastasis.
Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice.
Thrombospondin-2 overexpression in the skin of transgenic mice reduces the susceptibility to chemically induced multistep skin carcinogenesis.
Thrombospondin-2 plays a protective role in multistep carcinogenesis: a novel host anti-tumor defense mechanism.
Carcinoma
A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck.
An investigation into the potential role of brain angiogenesis inhibitor protein 3 (BAI3) in the tumorigenesis of small-cell carcinoma: a review of the surrounding literature.
An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma.
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review.
Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review.
Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines.
Angiogenesis inhibitor TNP-470 inhibits growth and metastasis of a hormone-independent rat prostatic carcinoma cell line.
Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma.
Anti-tumor effect of radiation response by combined treatment with angiogenesis inhibitor, TNP-470, in oral squamous cell carcinoma.
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.
Antiangiogenic Therapeutic Potential of Peptides Derived from the Molecular Motor KIF13B that Transports VEGFR2 to Plasmalemma in Endothelial Cells.
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.
Antitumor effect of arterial administration of a medium-chain triglyceride solution of an angiogenesis inhibitor, TNP-470, in rabbits bearing VX-2 carcinoma.
Antitumor effects of angiogenesis inhibitor 0-(chloroacetyl-carbamoyl) fumagillol (TNP-470) against murine renal cell carcinoma.
Antitumor effects of angiogenesis inhibitor TNP-470 in rabbits bearing VX-2 carcinoma by arterial administration of microspheres and oil solution.
Arresten, a collagen-derived angiogenesis inhibitor, suppresses invasion of squamous cell carcinoma.
Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian "Real-World" SAX Study.
Brain-specific angiogenesis inhibitor 1 is a putative factor for inhibition of neovascular formation in renal cell carcinoma.
cis-Diamminedichloroplatinum-resistant cell lines derived from human epithelial ovarian carcinoma express increased susceptibility to angiogenesis inhibitor TNP-470.
Co-opted JNK/SAPK signaling in Wnt/beta-catenin-induced tumorigenesis.
Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: Results from a medical chart review study?
Development and validation of an HPLC-UV method for pazopanib quantification in human plasma and application to patients with cancer in routine clinical practice.
DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets.
Docetaxel enhances the therapeutic effect of the angiogenesis inhibitor TNP-470 (AGM-1470) in metastatic human transitional cell carcinoma.
Effects of the angiogenesis inhibitor angiostatin on the growth of CC531 colon carcinoma cells in vitro and in a laparoscopic animal model of peritoneal carcinomatosis.
Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.
Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470) and cytotoxic agents in mice.
Exophytic parietal skin metastases of renal cell carcinoma.
Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization.
Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases.
Fast and Straightforward Method for the Quantification of Pazopanib in Human Plasma Using LC-MS/MS.
Frequent administration of angiogenesis inhibitor TNP-470 (AGM-1470) at an optimal biological dose inhibits tumor growth and metastasis of metastatic human transitional cell carcinoma in the urinary bladder.
gro-beta, a -C-X-C- chemokine, is an angiogenesis inhibitor that suppresses the growth of Lewis lung carcinoma in mice.
Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin.
Impaired coronary flow reserve in metastatic cancer patients treated with sunitinib.
Induction of G1 arrest and selective growth inhibition by lactacystin in human umbilical vein endothelial cells.
Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4.
Inhibition of liver metastasis of human gastric carcinoma by angiogenesis inhibitor TNP-470.
Inhibition of liver metastasis of human pancreatic carcinoma by angiogenesis inhibitor TNP-470 in combination with cisplatin.
Inhibition of tumor growth through suppression of angiogenesis by brain-specific angiogenesis inhibitor 1 gene transfer in murine renal cell carcinoma.
Inhibitory effect of angiogenesis inhibitor TNP-470 on human ACHN renal cell carcinoma.
Intra-tumor injection of an angiogenesis inhibitor, TNP-470, in rabbits bearing VX2 carcinoma of the tongue.
Long non-coding RNA ADAMTS9-AS2 inhibits liver cancer cell proliferation, migration and invasion.
Melatonin-triggered post-transcriptional and post-translational modifications of ADAMTS1 coordinately retard tumorigenesis and metastasis of renal cell carcinoma.
Mouse endostatin inhibits the formation of lung and liver metastases.
Neoadjuvant Therapy of Cervical Carcinoma with the Angiogenesis Inhibitor Bevacizumab: a Single-Centre Analysis.
Neoangiogenesis and p53 protein in lung cancer: their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression.
Patient Benefit-Risk Preferences for Targeted Agents in the Treatment of Renal Cell Carcinoma.
Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.
Pazopanib in Metastatic Renal Cancer: A "Real-World" Experience at National Cancer Institute "Fondazione G. Pascale".
Pazopanib-Induced Severe Acute Pancreatitis.
Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma.
Roles of intrinsic angiogenesis inhibitor, vasohibin, in cervical carcinomas.
Suppression of tumor growth and downregulation of platelet-derived endothelial cell growth factor / thymidine phosphorylase in tumor cells by angiogenesis inhibitor TNP-470.
Synthesis and preliminary evaluation of 5,7-dimethyl-2-aryl-3H-pyrrolizin-3-ones as angiogenesis inhibitors.
The antiangiogenic agent ZD4190 prevents tumour outgrowth in a model of minimal residual carcinoma in deep tissues.
The discovery of antiangiogenic molecules: a historical review.
Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo.
[An experimental study of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of Lewis lung carcinoma]
[Antitumor effect of the angiogenesis inhibitor, TNP470, on squamous cell carcinoma cells in head and neck cancer]
[Combining of TNP-470 and 5-Fu in inhibition of adenoid cystic carcinoma in nude mice model]
[Effect of Angiogenesis inhibitor (TNP-470) on the morphology of GNM cell line in vitro]
[Inhibition of liver metastases in rabbits by arterial infusion of angiogenesis inhibitor, TNP-470]
Carcinoma, Adenoid Cystic
[Combining of TNP-470 and 5-Fu in inhibition of adenoid cystic carcinoma in nude mice model]
Carcinoma, Ductal
Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma.
Carcinoma, Hepatocellular
Angiogenesis inhibitor TNP-470 can suppress hepatocellular carcinoma growth without retarding liver regeneration after partial hepatectomy.
Angiogenesis inhibitor TNP-470 suppresses the progression of experimentally-induced hepatocellular carcinoma in rats.
Expression of METH-1 and METH-2 in pancreatic cancer.
Inhibitory effect of the angiogenesis inhibitor TNP-470 on tumor growth and metastasis in nude mice bearing human hepatocellular carcinoma.
PI3K? inhibitor impairs AKT phosphorylation and synergizes with novel angiogenesis inhibitor AL3810 in human hepatocellular carcinoma.
Regulation of angiogenesis in human hepatomas: possible involvement of p53-inducible inhibitor of vascular endothelial cell proliferation.
Saffron-Based Crocin Prevents Early Lesions of Liver Cancer: In vivo, In vitro and Network Analyses.
Sorafenib-Loaded Nanoparticles Based on Biodegradable Dendritic Polymers for Enhanced Therapy of Hepatocellular Carcinoma.
SP1 and USF differentially regulate ADAMTS1 gene expression under normoxic and hypoxic conditions in hepatoma cells.
The angiogenesis inhibitor TNP-470 (AGM-1470) improves long-term survival of rats with liver metastasis.
The Neutrophil-to-Lymphocyte Ratio (NLR) Predicts the Prognosis of Unresectable Intermediate and Advanced Hepatocellular Carcinoma Treated with Apatinib.
Upregulation of vasohibin-1 expression with angiogenesis and poor prognosis of hepatocellular carcinoma after curative surgery.
[Inhibitory effects of ampelopsin on angiogenesis]
[Vascular and renal effects of anti-angiogenic therapy]
Carcinoma, Lewis Lung
Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma.
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.
Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470) and cytotoxic agents in mice.
Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases.
gro-beta, a -C-X-C- chemokine, is an angiogenesis inhibitor that suppresses the growth of Lewis lung carcinoma in mice.
[An experimental study of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of Lewis lung carcinoma]
Carcinoma, Non-Small-Cell Lung
Aberrant methylation of ADAMTS1 in non-small cell lung cancer.
BAI1 nuclear expression reflects the survival of nonsmoking non-small cell lung cancer patients.
CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo.
Enhanced anti-tumor and anti-angiogenic effects of metronomic cyclophosphamide combined with Endostar in a xenograft model of human lung cancer.
Identification of a novel tumor angiogenesis inhibitor targeting Shh/Gli1 signaling pathway in Non-small cell lung cancer.
Incidence and clinical implication of tumor cavitation in patients with advanced non-small cell lung cancer induced by Endostar, an angiogenesis inhibitor.
Neoangiogenesis and p53 protein in lung cancer: their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression.
Pazopanib diminishes non-small cell lung cancer (NSCLC) growth and metastases in vivo.
Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer.
Phase I clinical study of the angiogenesis inhibitor TSU-68 combined with carboplatin and paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer.
Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib.
The diagnostic significance of circulating lncRNA ADAMTS9-AS2 tumor biomarker in non-small cell lung cancer among the Egyptian population.
The Therapeuatic Effect of Endostar on Soft Carotid Plaque Neovascularization in Patients with Non-small Cell Lung Cancer.
Tumor Progression of Non-Small Cell Lung Cancer Controlled by Albumin and Micellar Nanoparticles of Itraconazole, a Multitarget Angiogenesis Inhibitor.
[Recombinant adenovirus expressing wild-type p53 is antiagiogenic--implication for lung cancer gene therapy]
Carcinoma, Ovarian Epithelial
cis-Diamminedichloroplatinum-resistant cell lines derived from human epithelial ovarian carcinoma express increased susceptibility to angiogenesis inhibitor TNP-470.
Carcinoma, Papillary
Expression of wild-type p53 tumor suppressor gene and its possible involvement in the apoptosis of thyroid tumors.
Carcinoma, Renal Cell
An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma.
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review.
Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review.
Antitumor effects of angiogenesis inhibitor 0-(chloroacetyl-carbamoyl) fumagillol (TNP-470) against murine renal cell carcinoma.
Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian "Real-World" SAX Study.
Brain-specific angiogenesis inhibitor 1 is a putative factor for inhibition of neovascular formation in renal cell carcinoma.
Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: Results from a medical chart review study?
Development and validation of an HPLC-UV method for pazopanib quantification in human plasma and application to patients with cancer in routine clinical practice.
Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.
Exophytic parietal skin metastases of renal cell carcinoma.
Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization.
Fast and Straightforward Method for the Quantification of Pazopanib in Human Plasma Using LC-MS/MS.
Impaired coronary flow reserve in metastatic cancer patients treated with sunitinib.
Inhibition of tumor growth through suppression of angiogenesis by brain-specific angiogenesis inhibitor 1 gene transfer in murine renal cell carcinoma.
Inhibitory effect of angiogenesis inhibitor TNP-470 on human ACHN renal cell carcinoma.
Long non-coding RNA ADAMTS9-AS2 inhibits liver cancer cell proliferation, migration and invasion.
Melatonin-triggered post-transcriptional and post-translational modifications of ADAMTS1 coordinately retard tumorigenesis and metastasis of renal cell carcinoma.
Mouse endostatin inhibits the formation of lung and liver metastases.
Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma.
Patient Benefit-Risk Preferences for Targeted Agents in the Treatment of Renal Cell Carcinoma.
Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.
Pazopanib in Metastatic Renal Cancer: A "Real-World" Experience at National Cancer Institute "Fondazione G. Pascale".
Pazopanib-Induced Severe Acute Pancreatitis.
Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma.
Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma.
Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients.
Synthesis and preliminary evaluation of 5,7-dimethyl-2-aryl-3H-pyrrolizin-3-ones as angiogenesis inhibitors.
The expression of tumstatin is down-regulated in renal carcinoma.
Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
Carcinoma, Squamous Cell
Arresten, a collagen-derived angiogenesis inhibitor, suppresses invasion of squamous cell carcinoma.
Co-opted JNK/SAPK signaling in Wnt/beta-catenin-induced tumorigenesis.
Suppression of tumor growth and downregulation of platelet-derived endothelial cell growth factor / thymidine phosphorylase in tumor cells by angiogenesis inhibitor TNP-470.
[Antitumor effect of the angiogenesis inhibitor, TNP470, on squamous cell carcinoma cells in head and neck cancer]
Carcinoma, Transitional Cell
Docetaxel enhances the therapeutic effect of the angiogenesis inhibitor TNP-470 (AGM-1470) in metastatic human transitional cell carcinoma.
Frequent administration of angiogenesis inhibitor TNP-470 (AGM-1470) at an optimal biological dose inhibits tumor growth and metastasis of metastatic human transitional cell carcinoma in the urinary bladder.
Carcinosarcoma
Antitumor activity of a medium-chain triglyceride solution of the angiogenesis inhibitor TNP-470 (AGM-1470) when administered via the hepatic artery to rats bearing Walker 256 carcinosarcoma in the liver.
Effect of angiogenesis inhibitor TNP-470 on the growth, blood flow, and microvessel density in xenografts of human uterine carcinosarcoma in nude mice.
TNP-470 inhibits growth and the production of vascular endothelial growth factor of uterine carcinosarcoma cells in vitro.
Cardiomegaly
Cardiac-specific mindin overexpression attenuates cardiac hypertrophy via blocking AKT/GSK3{beta} and TGF-{beta}1-Smad signalling.
Disruption of mindin exacerbates cardiac hypertrophy and fibrosis.
Cardiomyopathies
ADAMs family and relatives in cardiovascular physiology and pathology.
Cardiovascular Diseases
Endostatin inhibits T-type Ca2+ channel current in guinea pig ventricular myocyte.
The impact of parathyroidectomy on serum ADAMTS1, ADAMTS4 levels, insulin resistance, and subclinical cardiovascular disease in primary hyperparathyroidism.
Cervical Intraepithelial Neoplasia
Effects of difluoromethylornithine on growth inhibition and apoptosis in human cervical epithelial and cancerous cell lines.
Chondroma
ADAMTS1 is regulated by interleukin-1beta, not by hypoxia, in chondrosarcoma.
Chondrosarcoma
ADAMTS1 is regulated by interleukin-1beta, not by hypoxia, in chondrosarcoma.
Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo.
[Drug design of angiogenesis inhibitor for chondrosarcoma treatment]
Choriocarcinoma
Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo.
Choroidal Neovascularization
A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2.
Apparent receptor-mediated activation of Ca2+-dependent conductive Cl- transport by shark-derived polyaminosterols.
Inhibition of choroidal neovascularization by homoisoflavanone, a new angiogenesis inhibitor.
Inhibition of choroidal neovascularization by topical application of angiogenesis inhibitor vasostatin.
Inhibition of experimental choroidal neovascularization by an anti-growth agent inhibiting vascular endothelial development.
Light-responsive nanoparticle depot to control release of a small molecule angiogenesis inhibitor in the posterior segment of the eye.
Liposomes and nanotechnology in drug development: focus on ocular targets.
MicroRNA-195a-3p inhibits angiogenesis by targeting Mmp2 in murine mesenchymal stem cells.
Suppression of choroidal neovascularization by intramuscular polymer-based gene delivery of vasostatin.
Suppression of Choroidal Neovascularization by Intravitreal Injection of Liposomal SU5416.
Colonic Neoplasms
A novel angiogenesis inhibitor impairs lovo cell survival via targeting against human VEGFR and its signaling pathway of phosphorylation.
A novel angiogenesis inhibitor, Ki23057, is useful for preventing the progression of colon cancer and the spreading of cancer cells to the liver.
A role for antiangiogenic therapy in breast cancer.
ADAMTS1, CRABP1, and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis.
Angiogenesis inhibitor TNP-470 suppresses growth of peritoneal disseminating foci of human colon cancer line Lovo.
Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression.
Comparison of the inhibitory effect of the angiogenesis inhibitor, TNP-470, and mitomycin C on the growth and liver metastasis of human colon cancer.
Contribution of angiogenesis to the progression of colon cancer: possible inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and hepatic metastasis.
DMPPQA, a novel angiogenesis inhibitor, induces apoptosis in human colon cancer HCT-116 cells and HUVECs.
Down regulation of c-Myc and induction of an angiogenesis inhibitor, thrombospondin-1, by 5-FU in human colon cancer KM12C cells.
Effect of angiogenesis inhibitor SU6668 in combination with 5-Fu on liver metastasis from transplantation tumors of human colorectal cancer in nude mice.
Prevention of hepatic metastasis of human colon cancer by angiogenesis inhibitor TNP-470.
Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model.
Targeted agents for adjuvant therapy of colon cancer.
The effect of angiogenesis inhibitor TNP-470 against postoperative lung metastasis following removal of orthotopic transplanted human colon cancer: an experimental study.
The suppression of postoperative liver metastasis caused by the continuous intraportal infusion of angiogenesis inhibitor FR-118487 in a rabbit colon cancer model.
[Construction and activity of recombinant adeno-associated virus expressing vasostatin]
[Inhibition of growth and metastases of human colon cancer xenograft in nude mice by angiogenesis inhibitor endostatin]
[Inhibitory effects of TNP-470 in combination with 5-fluorouracil on growth of human colon cancer]
[Suppression of postoperative liver metastases from colon cancer by continuous intraportal infusion of an angiogenesis inhibitor FR-118487]
Colorectal Neoplasms
A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer.
ADAMTS1, CRABP1, and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis.
Angiogenesis as a therapeutic target in arthritis in 2011: learning the lessons of the colorectal cancer experience.
Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer.
Angiogenesis inhibitors as therapeutic agents in cancer: Challenges and future directions.
Angiogenesis inhibitors: perspectives for medical, surgical and radiation oncology.
Anti-angiogenic therapy for colorectal cancer: on the way to getting better!
Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression.
Association of CD133 polymorphisms and response to bevacizumab in patients with metastatic colorectal cancer.
Bevacizumab-related surgical site complication despite primary tumor resection in colorectal cancer patients.
Brain-specific angiogenesis inhibitor 1 expression is inversely correlated with vascularity and distant metastasis of colorectal cancer.
Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer.
Current progress in targeted therapy for colorectal cancer.
Effect of angiogenesis inhibitor SU6668 in combination with 5-Fu on liver metastasis from transplantation tumors of human colorectal cancer in nude mice.
Efficacy of an angiogenesis inhibitor, TNP-470, in xenotransplanted human colorectal cancer with high metastatic potential.
Expression of angiostatic factors in colorectal cancer.
Growth inhibition of liver metastases by the anti-angiogenic drug TNP-470.
Immunotherapy of tumor by targeting angiogenesis.
Inflammation and uPAR-Expression in Colorectal Liver Metastases in Relation to Growth Pattern and Neo-adjuvant Therapy.
Late anastomotic breakdown with bevacizumab in colorectal cancers, a case-based review.
Late anastomotic colonic dehiscence due to antiangiogenic treatment, a specific drug-class complication requiring specific treatment: An example of pazopanib complication.
Late anastomotic colonic dehiscence due to antiangiogenic treatment, a specific drug-class complication requiring specific treatment: an example of pazopanib complication.
Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer.
New drugs 05, part I.
New Insights Into Implementation of Mesenchymal Stem Cells in Cancer Therapy: Prospects for Anti-angiogenesis Treatment.
Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients.
Prevention of hepatic and peritoneal metastases by the angiogenesis inhibitor fr-118487 after removal of growing tumor in mice.
Real-World Evidence on Second-Line Treatment of Metastatic Colorectal Cancer Using Fluoropyrimidine, Irinotecan, and Angiogenesis Inhibitor.
Second-line option for colorectal cancer.
Therapeutic approaches of angiogenesis inhibition: are we tackling the problem at the right level?
Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer.
[Inhibitory effect of angiogenesis inhibitor YH-16 in combination with 5-FU on liver metastasis of colorectal cancer]
[Inhibitory effect of angiogenesis inhibitor YH-16 on liver metastases from colorectal cancer]
Corneal Neovascularization
Inhibition of corneal angiogenesis by local application of vasostatin.
Inhibition of tumor angiogenesis by oral etoposide.
Lipid-mediated delivery of brain-specific angiogenesis inhibitor 1 gene reduces corneal neovascularization in an in vivo rabbit model.
Coronary Artery Disease
Association of circulating angiogenesis inhibitors and asymmetric dimethyl arginine with coronary plaque burden.
Early-onset coronary artery disease after pediatric kidney transplantation: implicating the angiogenesis inhibitor, endostatin.
miR-365b-3p inhibits the cell proliferation and migration of human coronary artery smooth muscle cells by directly targeting ADAMTS1 in coronary atherosclerosis.
Coronary Disease
Association between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapy.
COVID-19
Effects of SARS-CoV-2 on Cardiovascular System: The Dual Role of Angiotensin-Converting Enzyme 2 (ACE2) as the Virus Receptor and Homeostasis Regulator-Review.
Estrogen receptors are linked to angiotensin-converting enzyme 2 (ACE2), ADAM metallopeptidase domain 17 (ADAM-17), and transmembrane protease serine 2 (TMPRSS2) expression in the human atrium: insights into COVID-19.
Dementia
Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A?, tau, immunity and lipid processing.
Dermatitis, Contact
Novel anti-inflammatory properties of the angiogenesis inhibitor vasostatin.
Diabetic Nephropathies
Amelioration of renal alterations in obese type 2 diabetic mice by vasohibin-1, a negative feedback regulator of angiogenesis.
Deletion of pro-angiogenic factor vasohibin-2 ameliorates glomerular alterations in a mouse diabetic nephropathy model.
Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy.
Diabetic Retinopathy
Eponemycin, a novel antibiotic, is a highly powerful angiogenesis inhibitor.
Potent inhibition of angiogenesis by wortmannin, a fungal metabolite.
Recombinant human maspin inhibits high glucose-induced oxidative stress and angiogenesis of human retinal microvascular endothelial cells via PI3K/AKT pathway.
Release of the angiogenesis inhibitor angiostatin in patients with proliferative diabetic retinopathy: association with retinal photocoagulation.
Tranilast inhibits the proliferation, chemotaxis and tube formation of human microvascular endothelial cells in vitro and angiogenesis in vivo.
Dyspnea
[Rendu-Osler-Weber disease : More than just a nosebleed].
Endometrial Neoplasms
A prodrug of green tea polyphenol (-)-epigallocatechin-3-gallate (Pro-EGCG) serves as a novel angiogenesis inhibitor in endometrial cancer.
Expression of vasohibin as a novel endothelium-derived angiogenesis inhibitor in endometrial cancer.
Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo.
PGF2?-F-prostanoid receptor signalling via ADAMTS1 modulates epithelial cell invasion and endothelial cell function in endometrial cancer.
Endometriosis
2-methoxyestradiol inhibits hypoxia-inducible factor-1{alpha} and suppresses growth of lesions in a mouse model of endometriosis.
A novel angiogenesis inhibitor bevacizumab induces apoptosis in the rat endometriosis model.
Endostatin inhibits the growth of endometriotic lesions but does not affect fertility.
Lower growth arrest-specific 5 level in endometrium is related to endometriosis via promoting cell proliferation and angiogenesis.
Short synthetic endostatin peptides inhibit endothelial migration in vitro and endometriosis in a mouse model.
Therapeutic effect of angiostatin gene transfer in a murine model of endometriosis.
Epistaxis
Does severe bleeding in HHT patients respond to intravenous bevacizumab? Review of the literature and case series.
Fibrosarcoma
ADAMTS1 contributes to the acquisition of an endothelial-like phenotype in plastic tumor cells.
Angiostatin formation involves disulfide bond reduction and proteolysis in kringle 5 of plasmin.
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.
Inhibition of lymphatic metastasis in a syngeneic rat fibrosarcoma model by an angiogenesis inhibitor, AGM-1470.
Fissure in Ano
Angiogenesis inhibitors and symptomatic anal ulcers in metastatic colorectal cancer patients (*).
Gastrointestinal Diseases
Safety profile of poly (ADP-ribose) polymerase (PARP) inhibitors in cancer: a network meta-analysis of randomized controlled trials.
Gastrointestinal Stromal Tumors
Impaired coronary flow reserve in metastatic cancer patients treated with sunitinib.
Synthesis and preliminary evaluation of 5,7-dimethyl-2-aryl-3H-pyrrolizin-3-ones as angiogenesis inhibitors.
Giant Cell Tumors
Interferon Alfa-2b for Recurrent and Metastatic Giant Cell Tumor of the Spine: Report of Two Cases.
Glioblastoma
A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis.
ADAMTS1 Supports Endothelial Plasticity of Glioblastoma Cells with Relevance for Glioma Progression.
Angiogenesis inhibitor DC101 delays growth of intracerebral glioblastoma but induces morbidity when combined with irradiation.
Antiangiogenic activity of BAI1 in vivo: implications for gene therapy of human glioblastomas.
Association of Rapidly Progressive Moyamoya Syndrome With Bevacizumab Treatment for Glioblastoma in a Child With Neurofibromatosis Type 1.
Brain angiogenesis inhibitor 1 is differentially expressed in normal brain and glioblastoma independently of p53 expression.
Case Report: Management of Persistent Dural Anastomotic Dehiscence in a Patient Treated With Bevacizumab.
Cloning and characterization of BAI2 and BAI3, novel genes homologous to brain-specific angiogenesis inhibitor 1 (BAI1).
Cutaneous thrombogenic vasculopathy associated with bevacizumab therapy.
Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice.
Methylation and silencing of the Thrombospondin-1 promoter in human cancer.
Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).
Relevance of IGFBP2 proteolysis in glioma and contribution of the extracellular protease ADAMTS1.
The Role of a Single Angiogenesis Inhibitor in the Treatment of Recurrent Glioblastoma Multiforme: A Meta-Analysis and Systematic Review.
[Therapeutic effect of brain-specific angiogenesis inhibitor 1 on glioblastoma: an animal experiment]
[Use of angioneogenesis inhibitor monoclonal antibody following standard therapy in recurrent or progressive glioblastoma multiforme].
Glioma
ADAMTS1 Supports Endothelial Plasticity of Glioblastoma Cells with Relevance for Glioma Progression.
Angiogenesis and antiangiogenic therapy for malignant gliomas.
Anti-proliferative effects of TNP-470 on human malignant glioma in vivo: potent inhibition of tumor angiogenesis.
Continuous release of endostatin from microencapsulated engineered cells for tumor therapy.
Effects of tetrandrine on glioma cell malignant phenotype via inhibition of ADAM17.
Expression of brain-specific angiogenesis inhibitor 3 (BAI3) in normal brain and implications for BAI3 in ischemia-induced brain angiogenesis and malignant glioma.
High-grade glioma before and after treatment with radiation and Avastin: initial observations.
Histone H3.3K27M Mobilizes Multiple Cancer/Testis (CT) Antigens in Pediatric Glioma.
Human glioma cell BT325 expresses a proteinase that converts human plasminogen to kringle 1-5-containing fragments.
Hyperthermia exhibits anti-vascular activity in the s.c. BT4An rat glioma: lack of interaction with the angiogenesis inhibitor batimastat.
Insulin receptor, IRS1, IRS2, INSIG1, INSIG2, RRAD, and BAIAP2 gene expressions in glioma U87 cells with ERN1 loss of function: effect of hypoxia and glutamine or glucose deprivation.
Isthmin inhibits glioma growth through antiangiogenesis in vivo.
Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A.
Local delivery of angiogenesis-inhibitor minocycline combined with radiotherapy and oral temozolomide chemotherapy in 9L glioma.
Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models.
Relevance of IGFBP2 proteolysis in glioma and contribution of the extracellular protease ADAMTS1.
T11TS impedes glioma angiogenesis by inhibiting VEGF signaling and pro-survival PI3K/Akt/eNOS pathway with concomitant upregulation of PTEN in brain endothelial cells.
T11TS inhibits Angiopoietin-1/Tie-2 signaling, EGFR activation and Raf/MEK/ERK pathway in brain endothelial cells restraining angiogenesis in glioma model.
Targeting angiogenesis inhibits tumor infiltration and expression of the pro-invasive protein SPARC.
Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470.
Glycogen Storage Disease Type VI
Comparative scRNA-seq Reveals Liver Metastasis-Specific Targets in a Patient with Small Intestinal Neuroendocrine Cancer.
Granuloma
Differential transcriptomics in sarcoidosis lung and lymph node granulomas with comparisons to pathogen-specific granulomas.
Experience with anti-angiogenic therapy of giant cell granuloma of the facial bones.
Regulation of angiogenesis and matrix remodeling by localized, matrix-mediated antisense gene delivery.
Granuloma, Giant Cell
Experience with anti-angiogenic therapy of giant cell granuloma of the facial bones.
Granulosa Cell Tumor
Response to antiangiogenesis therapy in a patient with advanced adult-type testicular granulosa cell tumor.
Head and Neck Neoplasms
[Antitumor effect of the angiogenesis inhibitor, TNP470, on squamous cell carcinoma cells in head and neck cancer]
Hearing Loss
ADAMTS1, MPDZ, MVD, and SEZ6: candidate genes for autosomal recessive nonsyndromic hearing impairment.
Heart Failure
Disruption of mindin exacerbates cardiac hypertrophy and fibrosis.
Hemangioendothelioma
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth.
Expression and purification of human endostatin from Hansenula polymorpha A16.
Treatment of murine hemangioendotheliomas with the angiogenesis inhibitor AGM-1470.
Hemangioma
A novel animal model for hemangiomas: inhibition of hemangioma development by the angiogenesis inhibitor TNP-470.
Clonality and altered behavior of endothelial cells from hemangiomas.
Endothelial progenitor cells from infantile hemangioma and from umbilical cord blood display unique cellular responses to endostatin.
Endothelial progenitor cells from infantile hemangioma and umbilical cord blood display unique cellular responses to endostatin.
Inhibition of angiogenesis.
Progressive growth of infantile cutaneous hemangiomas is directly correlated with hyperplasia and angiogenesis of adjacent epidermis and inversely correlated with expression of the endogenous angiogenesis inhibitor, IFN-beta.
The combination of antiangiogenic agents to inhibit primary tumor growth and metastasis.
Treatment of hemangioma with an angiogenesis inhibitor pingyangmycin.
Treatment of murine hemangioendotheliomas with the angiogenesis inhibitor AGM-1470.
Hemangiosarcoma
Combination therapy for scalp angiosarcoma using bevacizumab and chemotherapy: a case report and review of literature.
Hepatitis, Autoimmune
Effects of Combined Admistration of Imatinib and Sorafenib in a Murine Model of Liver Fibrosis.
Hepatoblastoma
Inhibition by an angiogenesis inhibitor, TNP-470, of the growth of a human hepatoblastoma heterotransplanted into nude mice.
Hyperparathyroidism, Primary
The impact of parathyroidectomy on serum ADAMTS1, ADAMTS4 levels, insulin resistance, and subclinical cardiovascular disease in primary hyperparathyroidism.
Hypersensitivity
Increased and prolonged inflammation and angiogenesis in delayed-type hypersensitivity reactions elicited in the skin of thrombospondin-2--deficient mice.
The Angiogenesis Inhibitor Thrombospondin-1 Inhibits Acute Cutaneous Hypersensitivity Reactions.
Hypertension
A case report of endorectal displacement of a right ureteral stent following radiochemotherapy and Bevacizumab.
An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition.
Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension.
Assessing Serum Levels of ADAMTS1 and ADAMTS4 as New Biomarkers for Patients with Type A Acute Aortic Dissection.
Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition.
Etiology of angiogenesis inhibition-related hypertension.
Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor.
Impaired coronary flow reserve in metastatic cancer patients treated with sunitinib.
Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis.
Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis.
Speckle-Tracking Echocardiography for Cardioncological Evaluation in Bevacizumab-Treated Colorectal Cancer Patients.
Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study.
Vascular endothelial growth factor polymorphisms: role in response and toxicity of tyrosine kinase inhibitors.
[Angiogenesis inhibitor therapies: focus on hypertension and kidney toxicity]
[Monitoring of hypertension in patients orally treated by angiogenesis inhibitor in daily practice].
[Vascular and renal effects of anti-angiogenic therapy]
Hypertension, Portal
Antiangiogenic and antifibrogenic activity of pigment epithelium-derived factor (PEDF) in bile duct-ligated portal hypertensive rats.
Hyperthyroidism
Serum level of the circulating angiogenesis inhibitor endostatin in patients with hyperthyroidism or hypothyroidism.
Hypothyroidism
Serum level of the circulating angiogenesis inhibitor endostatin in patients with hyperthyroidism or hypothyroidism.
Infarction, Middle Cerebral Artery
The quantification of ADAMTS expression in an animal model of cerebral ischemia using real-time PCR.
Infections
Brain angiogenesis inhibitor 1 is expressed by gastric phagocytes during infection with Helicobacter pylori and mediates the recognition and engulfment of human apoptotic gastric epithelial cells.
Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effect.
Infertility
Expression of ADAMTS1 during murine development.
Role of ADAMTS1 and ADAMTS5 in male infertility.
Infertility, Male
ADAMTS1 and ADAMTS5 metalloproteases produced by Sertoli cells: a potential diagnostic marker in azoospermia.
Role of ADAMTS1 and ADAMTS5 in male infertility.
Insulin Resistance
The impact of parathyroidectomy on serum ADAMTS1, ADAMTS4 levels, insulin resistance, and subclinical cardiovascular disease in primary hyperparathyroidism.
The miR-181d-regulated metalloproteinase Adamts1 enzymatically impairs adipogenesis via ECM remodeling.
Intracranial Aneurysm
Internal modulation of proteolysis in vascular extracellular matrix remodeling: role of ADAM metallopeptidase with thrombospondin type 1 motif 5 in the development of intracranial aneurysm rupture.
Iron Overload
Phase I trials of dexrazoxane and other potential applications for the agent.
Keloid
Partial epithelial-mesenchymal transition in keloid scars: regulation of keloid keratinocyte gene expression by transforming growth factor-?1.
Keratitis
Efficacy of fumagillin bicyclohexylamine on experimental corneal neovascularization in rat model.
Kidney Neoplasms
Angiogenesis and lymphangiogenesis: highlights of the past year.
Cutaneous thrombogenic vasculopathy associated with bevacizumab therapy.
Melatonin as a potential inhibitor of kidney cancer: A survey of the molecular processes.
Spontaneous enterocutaneous and rectovaginal fistula: potential complications during therapy with anti-angiogenic drugs in renal cancer.
Leukemia
Mapping transcription mechanisms from multimodal genomic data.
Leukemia, Lymphocytic, Chronic, B-Cell
Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia.
Liver Cirrhosis
Protease profiling of liver fibrosis reveals the adam metallopeptidase with thrombospondin type 1 motif, 1 as a central activator of TGF-?
Liver Diseases
In silico characterization of the interaction between LSKL peptide, a LAP-TGF-beta derived peptide, and ADAMTS1.
Protease profiling of liver fibrosis reveals the adam metallopeptidase with thrombospondin type 1 motif, 1 as a central activator of TGF-?
The Angiogenesis Inhibitor ALS-L1023 from Lemon-Balm Leaves Attenuates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease through Regulating the Visceral Adipose-Tissue Function.
Liver Neoplasms
Angiogenesis for tumor vascular normalization of Endostar on hepatoma 22 tumor-bearing mice is involved in the immune response.
Rifampicin as an oral angiogenesis inhibitor targeting hepatic cancers.
[Anti-tumor effects of an angiogenesis inhibitor, TNP-470 (AGM-1470) alone and in combination with cisplatinum, and changes in serum copper levels in liver cancer bearing rats]
Lung Injury
Pharmacology Study of the Multiple Angiogenesis Inhibitor RC28-E on Anti-Fibrosis in a Chemically Induced Lung Injury Model.
Lung Neoplasms
A catalog of genes homozygously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor gene.
A polymorphism in the angiogenesis inhibitor, endostatin, in lung cancer susceptibility.
Aberrant methylation of ADAMTS1 in non-small cell lung cancer.
Advanced Non-Small-Cell Lung Cancer in Elderly Patients: Patient Features and Therapeutic Management.
AE-941 (AEterna).
An investigation into the potential role of brain angiogenesis inhibitor protein 3 (BAI3) in the tumorigenesis of small-cell carcinoma: a review of the surrounding literature.
BAI1 nuclear expression reflects the survival of nonsmoking non-small cell lung cancer patients.
Characterization and secondary structure analysis of endostatin covalently modified by polyethylene glycol and low molecular weight heparin.
Clinical experience with the HER1/EGFR tyrosine kinase inhibitor erlotinib.
Cloning and Expression of Recombinant Human Endostatin in Periplasm of Escherichia coli Expression System.
CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo.
Co-opted JNK/SAPK signaling in Wnt/beta-catenin-induced tumorigenesis.
Effect of Culture Condition Variables on Human Endostatin Gene Expression in
Effect of tetramethylpyrazine combined with cisplatin on VEGF, KLF4 and ADAMTS1 in Lewis lung cancer mice.
Enhanced anti-tumor and anti-angiogenic effects of metronomic cyclophosphamide combined with Endostar in a xenograft model of human lung cancer.
First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation.
Gene Therapy in Orthotopic Lung Cancer Murine Model with Angiogenesis Inhibitor, Endostatin.
Identification and validation of novel circulating biomarkers for early diagnosis of lung cancer.
Identification of a novel tumor angiogenesis inhibitor targeting Shh/Gli1 signaling pathway in Non-small cell lung cancer.
Incidence and clinical implication of tumor cavitation in patients with advanced non-small cell lung cancer induced by Endostar, an angiogenesis inhibitor.
Long non-coding RNA ADAMTS9-AS2 inhibits liver cancer cell proliferation, migration and invasion.
Pazopanib diminishes non-small cell lung cancer (NSCLC) growth and metastases in vivo.
Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer.
Phase I clinical study of the angiogenesis inhibitor TSU-68 combined with carboplatin and paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer.
Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC).
Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib.
Prognostic values of VEGF and endostatin with malignant pleural effusions in patients with lung cancer.
Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer.
Suppression of lung tumor growth and metastasis in mice by adeno-associated virus-mediated expression of vasostatin.
The diagnostic significance of circulating lncRNA ADAMTS9-AS2 tumor biomarker in non-small cell lung cancer among the Egyptian population.
The impact of histological types on the efficacy of angiogenesis inhibitors in the treatment of advanced NSCLC: a meta-analysis of randomized controlled trials.
The Therapeuatic Effect of Endostar on Soft Carotid Plaque Neovascularization in Patients with Non-small Cell Lung Cancer.
Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer.
Tumor Progression of Non-Small Cell Lung Cancer Controlled by Albumin and Micellar Nanoparticles of Itraconazole, a Multitarget Angiogenesis Inhibitor.
[Anticancer drugs under pressure].
[Bevacizumab in the first-line therapy of advanced NSCLC]
[Inhibitory effect of angiogenesis inhibitor YH-16 on liver metastases from colorectal cancer]
[Recombinant adenovirus expressing wild-type p53 is antiagiogenic--implication for lung cancer gene therapy]
Lupus Erythematosus, Systemic
Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosus.
Lymphadenopathy
[Gastrectomy for Bleeding Gastric Cancer During Ramucirumab plus Paclitaxel Therapy-A Case Report].
Lymphatic Metastasis
Differentially regulated ADAMTS1, 8, and 18 in gastric adenocarcinoma.
Docetaxel enhances the therapeutic effect of the angiogenesis inhibitor TNP-470 (AGM-1470) in metastatic human transitional cell carcinoma.
Endogenous angiogenesis inhibitor vasohibin1 exhibits broad-spectrum antilymphangiogenic activity and suppresses lymph node metastasis.
Expression of ADAMTS1 and its correlation with angiogenesis in primary gastric cancer and lymph node metastasis.
Expression of METH-1 and METH-2 in pancreatic cancer.
Increased growth and incidence of lymph node metastases due to the angiogenesis inhibitor AGM-1470.
Inhibition of lymphatic metastasis in a syngeneic rat fibrosarcoma model by an angiogenesis inhibitor, AGM-1470.
Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.
Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice.
Lymphoma
Fumagillin, a potent angiogenesis inhibitor, induces Kaposi sarcoma-associated herpesvirus replication in primary effusion lymphoma cells.
Lymphoma, B-Cell
Expression Level of ADAMTS1 in Granulosa Cells of PCOS Patients Is Related to Granulosa Cell Function, Oocyte Quality, and Embryo Development.
Lymphoma, Non-Hodgkin
Combined effect of recombinant CD19 x CD16 diabody and thalidomide in a preclinical model of human B cell lymphoma.
Lymphoma, Primary Effusion
Fumagillin, a potent angiogenesis inhibitor, induces Kaposi sarcoma-associated herpesvirus replication in primary effusion lymphoma cells.
Macular Degeneration
Aortoduodenal Fistula in a Patient on Intravitreal Bevacizumab Injections: A Case Report.
Apparent receptor-mediated activation of Ca2+-dependent conductive Cl- transport by shark-derived polyaminosterols.
Implications of bevacizumab on vascular endothelial growth factor and endostatin in human choroidal neovascularisation.
Technology evaluation: pegaptanib, Eyetech/Pfizer.
Tranilast inhibits the proliferation, chemotaxis and tube formation of human microvascular endothelial cells in vitro and angiogenesis in vivo.
Macular Edema
Technology evaluation: pegaptanib, Eyetech/Pfizer.
Malocclusion
Candidate gene analyses of 3-dimensional dentoalveolar phenotypes in subjects with malocclusion.
Marfan Syndrome
Nitric oxide mediates aortic disease in mice deficient in the metalloprotease Adamts1 and in a mouse model of Marfan syndrome.
Regulation of Cellular Redox Signaling by Matricellular Proteins in Vascular Biology, Immunology, and Cancer.
Medulloblastoma
BAI1 Suppresses Medulloblastoma Formation by Protecting p53 from Mdm2-Mediated Degradation.
In comparative analysis of multi-kinase inhibitors for targeted medulloblastoma therapy pazopanib exhibits promising in vitro and in vivo efficacy.
The FDA approved PI3K inhibitor GDC-0941 enhances in vitro the anti-neoplastic efficacy of Axitinib against c-myc-amplified high-risk medulloblastoma.
Melanoma
ADAMTS1 contributes to the acquisition of an endothelial-like phenotype in plastic tumor cells.
Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin.
Angiogenic balance in human melanoma: expression of VEGF, bFGF, IL-8, PDGF and angiostatin in relation to vascular density of xenografts in vivo.
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.
Complete remission of Bomirski Ab amelanotic melanoma in hamsters treated with the angiogenesis inhibitor TNP-470.
Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.
Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents.
Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470) and cytotoxic agents in mice.
Extracellular Protease ADAMTS1 Is Required at Early Stages of Human Uveal Melanoma Development by Inducing Stemness and Endothelial-Like Features on Tumor Cells.
Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4.
Inhibition of xenografted human melanoma growth and prevention of metastasis development by dual antiangiogenic/antitumor activities of pigment epithelium-derived factor.
Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma.
Stroma-derived but not tumor ADAMTS1 is a main driver of tumor growth and metastasis.
Suppression of growth of Bomirski Ab melanoma and its metastasis in hamsters by angiogenesis inhibitor TNP-470.
Synergistic effect of the angiogenesis inhibitor TNP-470 and tumor necrosis factor (TNF) on Bomirski Ab melanoma in hamsters.
Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy.
Melanoma, Amelanotic
Complete remission of Bomirski Ab amelanotic melanoma in hamsters treated with the angiogenesis inhibitor TNP-470.
Melanoma, Experimental
Antitumor effect of B16 melanoma cells genetically modified with the angiogenesis inhibitor rnasin.
Meningitis, Bacterial
Case Report: Management of Persistent Dural Anastomotic Dehiscence in a Patient Treated With Bevacizumab.
Metabolic Syndrome
Antiangiogenic Herbal Composition Ob-X Reduces Abdominal Visceral Fat in Humans: A Randomized, Double-Blind, Placebo-Controlled Study.
Mucocutaneous Lymph Node Syndrome
Suppression of coronary vasculitis in a murine model of Kawasaki disease using an angiogenesis inhibitor.
Mucositis
Phase I trials of dexrazoxane and other potential applications for the agent.
Multiple Myeloma
A polymorphism in the angiogenesis inhibitor, endostatin, in multiple myeloma.
Angiogenesis-dependent diseases.
Thalidomide-induced bronchiolitis obliterans organizing pneumonia in a patient with multiple myeloma.
Thalidomide-induced organizing pneumonia.
Myocardial Infarction
A disintegrin and metalloproteinase with thrombospondin motif 1 (ADAMTS1) expression increases in acute aortic dissection.
ADAMTS1 is a unique hypoxic early response gene expressed by endothelial cells.
Diverse Functions of a Disintegrin and Metalloproteinase with Thrombospondin Motif-1.
Dynamic induction of ADAMTS1 gene in the early phase of acute myocardial infarction.
The Role of ADAMTS1 and Versican in Human Myocardial Infarction: A Postmortem Study.
Variants of ADAMTS1 modify the effectiveness of statins in reducing the risk of myocardial infarction.
Myocardial Ischemia
Angiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: a meta-analysis.
Myoclonic Epilepsies, Progressive
Genomic structure and alternative splicing of the insulin receptor tyrosine kinase substrate of 53-kDa protein.
Nasopharyngeal Carcinoma
Anti-tumor effect of angiogenesis inhibitor TNP-470 on the human nasopharyngeal carcinoma cell line NPC/HK1.
Combination of angiogenesis inhibitor TNP-470 with cytotoxic drugs in experimental therapy of nasopharyngeal carcinoma.
Effect of hypericin-mediated photodynamic therapy on the expression of vascular endothelial growth factor in human nasopharyngeal carcinoma.
Primary study in experimental antiangiogenic therapy of nasopharyngeal carcinoma with AGM-1470 (TNP-470).
Neoplasm Metastasis
A potential use of a synthetic retinoid TAC-101 as an orally active agent that blocks angiogenesis in liver metastases of human stomach cancer cells.
A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment.
A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft models.
Aberrant methylation of ADAMTS1 in non-small cell lung cancer.
ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis.
ADAMTS1 Promotes Adhesion to Extracellular Matrix Proteins and Predicts Prognosis in Early Stage Breast Cancer Patients.
ADAMTS1, a putative anti-angiogenic factor, is decreased in human prostate cancer.
Angiogenesis Inhibitor O-(Chloroacetyl-carbamoyl) fumagillol (TNP-470) Inhibits Tumor Angiogenesis, Growth and Spontaneous Metastasis of MKL-4 Human Breast Cancer Cells in Female Athymic Nude Mice.
Angiogenesis inhibitor TNP-470 inhibits growth and metastasis of a hormone-independent rat prostatic carcinoma cell line.
Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption.
Angiogenesis inhibitor TNP-470 prevents implanted liver metastases after partial hepatectomy in an experimental model without impairing wound healing.
Angiogenesis inhibitor Z24 induces endothelial cell apoptosis and suppresses tumor growth and metastasis.
Angiostatin inhibits bone metastasis formation in nude mice through a direct anti-osteoclastic activity.
Angiostatin is directly cytotoxic to tumor cells at low extracellular pH: a mechanism dependent on cell surface-associated ATP synthase.
Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma.
Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth.
Antiangiogenic Function of Antithrombin is Dependent on its Conformational Variation: Implication for Other Serpins.
Antitumor effects induced by the combination of TNP-470 as an angiogenesis inhibitor and lentinan as a biological response modifier in a rabbit spontaneous liver metastasis model.
Augmented anti-angiogenesis activity of polysulfated heparin-endostatin and polyethylene glycol-endostatin in alkali burn-induced corneal ulcers in rabbits.
Bee venom inhibits tumor angiogenesis and metastasis by inhibiting tyrosine phosphorylation of VEGFR-2 in LLC-tumor-bearing mice.
Brain-specific angiogenesis inhibitor 1 expression is inversely correlated with vascularity and distant metastasis of colorectal cancer.
Comparative scRNA-seq Reveals Liver Metastasis-Specific Targets in a Patient with Small Intestinal Neuroendocrine Cancer.
Comparison of the inhibitory effect of the angiogenesis inhibitor, TNP-470, and mitomycin C on the growth and liver metastasis of human colon cancer.
Contribution of angiogenesis to the progression of colon cancer: possible inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and hepatic metastasis.
Cutaneous metastases in renal cell carcinoma: a case report.
Differentially regulated ADAMTS1, 8, 9, and 18 in pancreas adenocarcinoma.
Differentially regulated ADAMTS1, 8, and 18 in gastric adenocarcinoma.
Docetaxel enhances the therapeutic effect of the angiogenesis inhibitor TNP-470 (AGM-1470) in metastatic human transitional cell carcinoma.
Downregulation of A disintegrin and metallopeptidase with thrombospondin motif type 1 by DNA hypermethylation in human gastric cancer.
Effect of angiogenesis inhibitor SU6668 in combination with 5-Fu on liver metastasis from transplantation tumors of human colorectal cancer in nude mice.
Effect of angiogenesis inhibitor TNP-470 on the progression of human gastric cancer xenotransplanted into nude mice.
Effects of Linomide on growth and metastasis of implanted human gastric cancer in nude mice.
Efficacy and safety of apatinib as third- or further-line therapy for patients with advanced NSCLC: a retrospective study.
Efficacy of the angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (AGM-1470) on osteosarcoma growth and lung metastasis in rats.
Elevated levels of urine angiostatin and plasminogen/plasmin in cancer patients.
Endogenous angiogenesis inhibitor vasohibin1 exhibits broad-spectrum antilymphangiogenic activity and suppresses lymph node metastasis.
Enhanced anti-angiogenesis and anti-tumor activity of endostatin by chemical modification with polyethylene glycol and low molecular weight heparin.
Enhanced antitumour efficacy by combining conventional chemotherapy with angiostatin or endostatin in a liver metastasis model.
Exophytic parietal skin metastases of renal cell carcinoma.
Expression of ADAMTS1 and its correlation with angiogenesis in primary gastric cancer and lymph node metastasis.
Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases.
Expression of METH-1 and METH-2 in pancreatic cancer.
Frequent administration of angiogenesis inhibitor TNP-470 (AGM-1470) at an optimal biological dose inhibits tumor growth and metastasis of metastatic human transitional cell carcinoma in the urinary bladder.
Genetic analysis of high-metastatic clone of RCT sarcoma in mice, and its growth regression in vivo in response to angiogenesis inhibitor TNP-470.
Genomic predictors of chemotherapy efficacy in advanced or recurrent gastric cancer in the GC0301/TOP002 phase III clinical trial.
Growth inhibition of liver metastases by the anti-angiogenic drug TNP-470.
HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice.
Importance of timing and length of administration of angiogenesis inhibitor TNP-470 in the treatment of K12/TRb colorectal hepatic metastases in BD-IX rats.
In vivo evaluation of microspheres containing the angiogenesis inhibitor, TNP-470, and the metastasis suppression with liver metastatic model implanted neuroblastoma.
Increased growth and incidence of lymph node metastases due to the angiogenesis inhibitor AGM-1470.
Inflammation and uPAR-Expression in Colorectal Liver Metastases in Relation to Growth Pattern and Neo-adjuvant Therapy.
Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity.
Inhibition of hepatic metastasis in mice treated with cell-binding domain of human fibronectin and angiogenesis inhibitor TNP-470.
Inhibition of liver metastasis of human gastric carcinoma by angiogenesis inhibitor TNP-470.
Inhibition of liver metastasis of human pancreatic carcinoma by angiogenesis inhibitor TNP-470 in combination with cisplatin.
Inhibition of tumor growth and metastasis by angiogenesis inhibitor TNP-470 on breast cancer cell lines in vitro and in vivo.
Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470; AGM-1470).
Inhibition of xenografted human melanoma growth and prevention of metastasis development by dual antiangiogenic/antitumor activities of pigment epithelium-derived factor.
Inhibitory effect of angiogenesis inhibitor TNP-470 on human ACHN renal cell carcinoma.
Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo.
Inhibitory Effect of the Angiogenesis Inhibitor O-(Chloroacetyl-carbamoyl)fumagillol(TNP-470) on Tumor Growth and Metastasis of Murine Mammary Tumor Cell Line (JYG-B)Inoculated in Female Nude Mice.
Inhibitory effect of the angiogenesis inhibitor TNP-470 on tumor growth and metastasis in nude mice bearing human hepatocellular carcinoma.
Inhibitory effect of TNP-470 on hepatic metastasis of mouse neuroblastoma.
Inhibitory effects of roxithromycin on tumor angiogenesis, growth and metastasis of mouse B16 melanoma cells.
Intra-arterial administration of the angiogenesis inhibitor TNP-470 blocks liver metastasis in a rabbit model.
Melatonin-triggered post-transcriptional and post-translational modifications of ADAMTS1 coordinately retard tumorigenesis and metastasis of renal cell carcinoma.
MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer.
NK4, an HGF antagonist, prevents hematogenous pulmonary metastasis by inhibiting adhesion of CT26 cells to endothelial cells.
Prevention of hepatic and peritoneal metastases by the angiogenesis inhibitor fr-118487 after removal of growing tumor in mice.
Prevention of hepatic metastasis of human colon cancer by angiogenesis inhibitor TNP-470.
Pterostilbene carboxaldehyde thiosemicarbazone, a resveratrol derivative inhibits 17?-Estradiol induced cell migration and proliferation in HUVECs.
Stroma-derived but not tumor ADAMTS1 is a main driver of tumor growth and metastasis.
Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.
Suppression of growth of Bomirski Ab melanoma and its metastasis in hamsters by angiogenesis inhibitor TNP-470.
Suppression of Peritoneal Metastases by Expression of Murine Endostatin cDNA.
Suppression of pulmonary metastasis by angiogenesis inhibitor TNP-470 in murine osteosarcoma.
Survival benefit of KRN7000 immune therapy in combination with TNP470 in hamster liver metastasis model of pancreatic cancer.
Targeting Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase in the Mutant (V600E) B-Raf Signaling Cascade Effectively Inhibits Melanoma Lung Metastases.
The ADAMTS1 protease gene is required for mammary tumor growth and metastasis.
The angiogenesis inhibitor TNP-470 (AGM-1470) improves long-term survival of rats with liver metastasis.
The combination of antiangiogenic agents to inhibit primary tumor growth and metastasis.
The E2F transcription factors regulate tumor development and metastasis in a mouse model of metastatic breast cancer.
The effect of angiogenesis inhibitor TNP-470 against postoperative lung metastasis following removal of orthotopic transplanted human colon cancer: an experimental study.
The effects of hypericin on ADAMTS and p53 gene expression in MCF-7 breast cancer cells.
The metalloproteinase ADAMTS1: A comprehensive review of its role in tumorigenic and metastatic pathways.
The prostatic environment suppresses growth of androgen-independent prostate cancer xenografts: An effect influenced by testosterone.
The suppression of postoperative liver metastasis caused by the continuous intraportal infusion of angiogenesis inhibitor FR-118487 in a rabbit colon cancer model.
Upregulation of lncRNA ADAMTS9-AS2 Promotes Salivary Adenoid Cystic Carcinoma Metastasis via PI3K/Akt and MEK/Erk Signaling.
Variable inhibition of thrombospondin 1 against liver and lung metastases through differential activation of metalloproteinase ADAMTS1.
[A man with blisters on hand and feet].
[Advances in the study of mechanisms of the tumor angiogenesis inhibitors]
[An experimental study of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of Lewis lung carcinoma]
[Cloning and antitumor activity of angiogenesis inhibitor HIAF-1]
[Effect of angiogenesis inhibitor Rg3 on the growth and metastasis of gastric cancer in SCID mice]
[Effect of angiogenesis inhibitor SU6668 on the growth and metastasis of gastric cancer in SCID mice]
[Effects of angiogenesis inhibitor TNP-470 to suppress the recurrence in the liver remnant after partial hepatectomy for liver metastases in rabbits]
[Effects of suramin in combination with Cisplatin on growth and metastasis of lung adenocarcinoma xenografts in mice.]
[Experimental study of the effect of angiogenesis inhibitor TNP-470 on the growth and metastasis of gastric cancer in vivo]
[Inhibition of growth and metastases of human colon cancer xenograft in nude mice by angiogenesis inhibitor endostatin]
[Inhibition of growth and metastasis of human gastric cancer implanted in nude mice by the angiogenesis inhibitor endostatin]
[Inhibition of liver metastases in rabbits by arterial infusion of angiogenesis inhibitor, TNP-470]
[Inhibitory effect of angiogenesis inhibitor YH-16 in combination with 5-FU on liver metastasis of colorectal cancer]
[Inhibitory effect of angiogenesis inhibitor YH-16 on liver metastases from colorectal cancer]
[Paths of innovative surgery in gastrointestinal cancer in our department]
[Suppression of peritoneal implantation by NK4 and its mechanisms]
[Suppression of postoperative liver metastases from colon cancer by continuous intraportal infusion of an angiogenesis inhibitor FR-118487]
Neoplasm Micrometastasis
Vascular endothelial growth factor increased by pulmonary surgery accelerates the growth of micrometastases in metastatic lung cancer.
Neoplasms
A case report of endorectal displacement of a right ureteral stent following radiochemotherapy and Bevacizumab.
A Double-Blind Randomized Discontinuation Phase-II Study of Sorafenib (BAY 43-9006) in Previously Treated Non-Small-Cell Lung Cancer Patients: Eastern Cooperative Oncology Group Study E2501.
A fragment of histidine-rich glycoprotein is a potent inhibitor of tumor vascularization.
A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin.
A hybrid protein comprising ATF domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent candidate for targeted cancer therapy.
A new tumor suppressor LncRNA ADAMTS9-AS2 is regulated by DNMT1 and inhibits migration of glioma cells.
A novel angiogenesis inhibitor, Ki23057, is useful for preventing the progression of colon cancer and the spreading of cancer cells to the liver.
A novel poly-naphthol compound ST104P suppresses angiogenesis by attenuating matrix metalloproteinase-2 expression in endothelial cells.
A novel tissue model for angiogenesis: evaluation of inhibitors or promoters in tissue level.
A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer.
A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors.
A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors.
A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points.
A proprotein convertase/MMP-14 proteolytic cascade releases a novel 40?kDa vasculostatin from tumor suppressor BAI1.
A role for antiangiogenic therapy in breast cancer.
A strategy to discover circulating angiogenesis inhibitors generated by human tumors.
A surrogate marker to monitor angiogenesis at last.
A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft models.
Aberrant methylation of ADAMTS1 in non-small cell lung cancer.
ADAM12 is a prognostic factor associated with an aggressive molecular subtype of high-grade serous ovarian carcinoma.
ADAM12 silencing promotes cellular apoptosis by activating autophagy in choriocarcinoma cells.
ADAMs in cancer cell proliferation and progression.
ADAMTS1 alters blood vessel morphology and TSP1 levels in LNCaP and LNCaP-19 prostate tumors.
ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis.
ADAMTS1 contributes to the acquisition of an endothelial-like phenotype in plastic tumor cells.
ADAMTS1 inhibits lymphangiogenesis by attenuating phosphorylation of the lymphatic endothelial cell-specific VEGF receptor.
ADAMTS1 interacts with, cleaves, and modifies the extracellular location of the matrix inhibitor tissue factor pathway inhibitor-2.
ADAMTS1 is regulated by interleukin-1beta, not by hypoxia, in chondrosarcoma.
ADAMTS1 Promotes Adhesion to Extracellular Matrix Proteins and Predicts Prognosis in Early Stage Breast Cancer Patients.
ADAMTS1 protease is required for a balanced immune cell repertoire and tumour inflammatory response.
ADAMTS1 Supports Endothelial Plasticity of Glioblastoma Cells with Relevance for Glioma Progression.
ADAMTS1, a putative anti-angiogenic factor, is decreased in human prostate cancer.
ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165.
ADAMTS1: a matrix metalloprotease with angioinhibitory properties.
AGM-1470, a potent angiogenesis inhibitor, prevents the entry of normal but not transformed endothelial cells into the G1 phase of the cell cycle.
Altered expression of genes regulating angiogenesis in experimental androgen-independent prostate cancer.
Alternative transcription of a shorter, non-anti-angiogenic thrombospondin-2 variant in cancer-associated blood vessels.
An angiogenesis inhibitor E7820 shows broad-spectrum tumor growth inhibition in a xenograft model: possible value of integrin alpha2 on platelets as a biological marker.
An investigation into the potential role of brain angiogenesis inhibitor protein 3 (BAI3) in the tumorigenesis of small-cell carcinoma: a review of the surrounding literature.
Anacardic Acid (6-Pentadecylsalicylic Acid) Inhibits Tumor Angiogenesis by Targeting Src/FAK/Rho GTPases Signaling Pathway.
Analysis of a bone metastasis gene expression signature in patients with bone metastasis from solid tumors.
Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate.
Angioarrestin: an antiangiogenic protein with tumor-inhibiting properties.
Angiogenesis and apoptosis.
Angiogenesis as a therapeutic target in arthritis in 2011: learning the lessons of the colorectal cancer experience.
Angiogenesis in atherosclerosis: gathering evidence beyond speculation.
Angiogenesis inhibitor DC101 delays growth of intracerebral glioblastoma but induces morbidity when combined with irradiation.
Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team.
Angiogenesis Inhibitor O-(Chloroacetyl-carbamoyl) fumagillol (TNP-470) Inhibits Tumor Angiogenesis, Growth and Spontaneous Metastasis of MKL-4 Human Breast Cancer Cells in Female Athymic Nude Mice.
Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines.
Angiogenesis inhibitor TNP-470 augments the effect of repeated arterial ischemia on growth but does not affect take in a rat liver tumor model.
Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption.
Angiogenesis inhibitor Z24 induces endothelial cell apoptosis and suppresses tumor growth and metastasis.
Angiogenesis inhibitor, TNP-470, suppresses growth of peritoneal disseminating foci.
Angiogenesis inhibitors and symptomatic anal ulcers in metastatic colorectal cancer patients (*).
Angiogenesis inhibitors as therapeutic agents in cancer: Challenges and future directions.
Angiogenesis inhibitors in a murine neuroblastoma model: quantitative assessment of intratumoral blood flow with contrast-enhanced gray-scale US.
Angiogenesis research: from laboratory to clinic.
Angiogenic factors are elevated in overweight and obese individuals.
Angiostatin inhibits bone metastasis formation in nude mice through a direct anti-osteoclastic activity.
Angiostatin is directly cytotoxic to tumor cells at low extracellular pH: a mechanism dependent on cell surface-associated ATP synthase.
Angiostatin.
Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma.
Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth.
Anti-angiogenic activity of ursodeoxycholic acid and its derivatives.
Anti-Angiogenic Effect of Orally Available Pemetrexed for Metronomic Chemotherapy.
Anti-cancer activity of Annexin V in murine melanoma model by suppressing tumor angiogenesis.
Anti-tumor effect of endostatin mediated by retroviral gene transfer in mice bearing renal cell carcinoma.
Anti-tumor effect of lentivirus-mediated gene transfer of alphastatin on Human glioma.
Antiangiogenesis signals by endostatin.
Antiangiogenesis therapy using a novel angiogenesis inhibitor, anginex, following radiation causes tumor growth delay.
Antiangiogenic and anticancer effect of an orally active low molecular weight heparin conjugates and its application to lung cancer chemoprevention.
Antiangiogenic effects of cucurbitacin-I.
Antiangiogenic Function of Antithrombin is Dependent on its Conformational Variation: Implication for Other Serpins.
Antiangiogenic Therapeutic Potential of Peptides Derived from the Molecular Motor KIF13B that Transports VEGFR2 to Plasmalemma in Endothelial Cells.
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.
Antiangiogenic treatment with the three thrombospondin-1 type 1 repeats recombinant protein in an orthotopic human pancreatic cancer model.
Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors.
Antitumor activity of the angiogenesis inhibitor TNP-470 on murine lymphoma/leukemia cells in vivo and in vitro.
Antitumor effect of 22-oxa-1 alpha,25-dihydroxyvitamin D3, a potent angiogenesis inhibitor, on rat mammary tumors induced by 7,12-dimethylbenz[a]anthracene.
Antitumor effect of arterial administration of a medium-chain triglyceride solution of an angiogenesis inhibitor, TNP-470, in rabbits bearing VX-2 carcinoma.
Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis.
Antitumor effect of the angiogenesis inhibitor TNP-470 and its combination effect with 5-FU and PSK in colon 26 tumors.
Antitumor effect of the angiogenesis inhibitor TNP-470 on human digestive organ malignancy.
Antitumor effect of TNP-470, an angiogenesis inhibitor, combined with ultrasound irradiation for human uterine sarcoma xenografts evaluated using contrast color Doppler ultrasound.
Antitumor effects induced by the combination of TNP-470 as an angiogenesis inhibitor and lentinan as a biological response modifier in a rabbit spontaneous liver metastasis model.
Antitumor effects of angiogenesis inhibitor TNP-470 in rabbits bearing VX-2 carcinoma by arterial administration of microspheres and oil solution.
Aortoduodenal Fistula in a Patient on Intravitreal Bevacizumab Injections: A Case Report.
Application of IVIM-DWI in Detecting the Tumor Vasculogenic Mimicry Under Antiangiogenesis Combined With Oxaliplatin Treatment.
Aspergillus, angiogenesis, and obesity: the story behind beloranib.
Association between CpG island methylation and microsatellite instability in colorectal cancer.
Augmented anti-angiogenesis activity of polysulfated heparin-endostatin and polyethylene glycol-endostatin in alkali burn-induced corneal ulcers in rabbits.
Autocrine expression of both endostatin and green fluorescent protein provides a synergistic antitumor effect in a murine neuroblastoma model.
Autophagic degradation of CCN2 (cellular communication network factor 2) causes cardiotoxicity of sunitinib.
Azithromycin effectively inhibits tumor angiogenesis by suppressing vascular endothelial growth factor receptor 2-mediated signaling pathways in lung cancer.
BAI1 acts as a tumor suppressor in lung cancer A549 cells by inducing metabolic reprogramming via the SCD1/HMGCR module.
BAIAP2L2 facilitates the malignancy of prostate cancer (PCa) via VEGF and apoptosis signaling pathways.
Beta-35 is a transferrin-derived inhibitor of angiogenesis and tumor growth.
Bevacizumab and near infrared probe conjugated iron oxide nanoparticles for vascular endothelial growth factor targeted MR and optical imaging.
Bevacizumab in clinical practice.
Bevacizumab-Based Chemotherapy Combined with Regional Deep Capacitive Hyperthermia in Metastatic Cancer Patients: A Pilot Study.
Bevacizumab-induced hypertension: Clinical presentation and molecular understanding.
Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies.
Biological regulation through protein disulfide bond cleavage.
Blocking transforming growth factor beta signaling in transgenic epidermis accelerates chemical carcinogenesis: a mechanism associated with increased angiogenesis.
Blocking tumor growth, invasion, and metastasis by maspin in a syngeneic breast cancer model.
Bone Marrow CX3CL1/Fractalkine is a New Player of the Pro-Angiogenic Microenvironment in Multiple Myeloma Patients.
Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice.
Brain-specific angiogenesis inhibitor 1 is a putative factor for inhibition of neovascular formation in renal cell carcinoma.
Breast cancer cells induce stromal fibroblasts to secrete ADAMTS1 for cancer invasion through an epigenetic change.
Butein Inhibits Angiogenesis of Human Endothelial Progenitor Cells via the Translation Dependent Signaling Pathway.
Candidate gene polymorphisms and risk of psoriasis: A pilot study.
Candidate therapeutic agents for hepatocellular cancer can be identified from phenotype-associated gene expression signatures.
Cartilage dysplasia and tissue mineralization in the rat following administration of a FGF receptor tyrosine kinase inhibitor.
Cerebral ischemic events in patients with advanced lung or prostate cancer.
Changes in BAI1 and nestin expression are prognostic indicators for survival and metastases in breast cancer and provide opportunities for dual targeted therapies.
Changes in the gene expression profile of A375 human melanoma cells induced by overexpression of multifunctional pigment epithelium-derived factor.
Characterization of a reduced form of plasma plasminogen as the precursor for angiostatin formation.
Characterization of PEDF: a multi-functional serpin family protein.
Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors.
Clinical pharmacology of anti-angiogenic drugs in oncology.
CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo.
Co-opted JNK/SAPK signaling in Wnt/beta-catenin-induced tumorigenesis.
Collaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment.
Combination effect of an angiogenesis inhibitor agm-1470 with 5'-deoxy-5-fluorouridine, and with hormonal drugs in dmba-induced rat mammary-tumors.
Combination of Caspy2 and IP-10 Gene Therapy Significantly Improves Therapeutic Efficacy Against Murine Malignant Neoplasm Growth and Metastasis.
Combination of the Tumor Angiogenesis Inhibitor Bevacizumab and Intratumoral Oncolytic Herpes Virus Injections as a Treatment Strategy for Human Gastric Cancers.
Combinational chemoprevention effect of celecoxib and an oral antiangiogenic LHD4 on colorectal carcinogenesis in mice.
Combined administration of PTX and S-HM-3 in TPGS/Solutol micelle system for oncotarget therapy.
Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors.
Construction of recombinant lentivirus vector for tumor vasoinhibitory peptide alphastatin gene delivery.
Construction of recombinant plasmid and prokaryotic expression in E.Coli and biological activity analysis of human placenta arresten gene.
Contribution of ADAMTS1 as a tumor suppressor gene in human breast carcinoma. Linking its tumor inhibitory properties to its proteolytic activity on nidogen-1 and nidogen-2.
Contribution of angiogenesis to the progression of colon cancer: possible inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and hepatic metastasis.
Control of tumor growth in animals by infusion of an angiogenesis inhibitor.
Cryptotanshinone, a novel tumor angiogenesis inhibitor, destabilizes tumor necrosis factor-? mRNA via decreasing nuclear-cytoplasmic translocation of RNA-binding protein HuR.
Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain.
Cutaneous thrombogenic vasculopathy associated with bevacizumab therapy.
Cyclic RGDyk-conjugated LMWH-taurocholate derivative as a targeting angiogenesis inhibitor.
Deeper Penetration into Tumor Tissues and Enhanced in Vivo Antitumor Activity of Liposomal Paclitaxel by Pretreatment with Angiogenesis Inhibitor SU5416.
Design, synthesis and biological evaluation of Lenalidomide derivatives as tumor angiogenesis inhibitor.
Development and validation of an HPLC-UV method for pazopanib quantification in human plasma and application to patients with cancer in routine clinical practice.
Development of pyogenic granuloma with strong vascular endothelial growth factor receptor-2 expression during ramucirumab treatment.
Differential expression of genes coding for EGF-like factors and ADAMTS1 following gonadotropin stimulation in normal and transformed human granulosa cells.
Differential roles of protein kinase C and pertussis toxin-sensitive G-binding proteins in modulation of melanoma cell proliferation and motility by thrombospondin 1.
Differentially regulated ADAMTS1, 8, and 18 in gastric adenocarcinoma.
Dihydroartemisinin inhibits endothelial cell proliferation through the suppression of the ERK signaling pathway.
Dihydroartemisinin targets VEGFR2 via the NF-?B pathway in endothelial cells to inhibit angiogenesis.
Dipalmitoylation of radicicol results in improved efficacy against tumor growth and angiogenesis in vivo.
Diverse Functions of a Disintegrin and Metalloproteinase with Thrombospondin Motif-1.
Docetaxel enhances the therapeutic effect of the angiogenesis inhibitor TNP-470 (AGM-1470) in metastatic human transitional cell carcinoma.
Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer Perspectives.
Downregulation of A disintegrin and metallopeptidase with thrombospondin motif type 1 by DNA hypermethylation in human gastric cancer.
Downregulation of tumstatin expression by overexpression of ornithine decarboxylase.
Dynamic (18)F-FDG-PET for monitoring treatment effect following anti-angiogenic therapy in triple-negative breast cancer xenografts.
Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.
Dynamic induction of ADAMTS1 gene in the early phase of acute myocardial infarction.
E1B-55kD-deleted oncolytic adenovirus armed with canstatin gene yields an enhanced anti-tumor efficacy on pancreatic cancer.
Effect of 15-deoxyspergualin, a microbial angiogenesis inhibitor, on the biological activities of bovine vascular endothelial cells.
Effect of an angiogenesis inhibitor on hepatic tumor perfusion and the implications for adjuvant cytotoxic therapy.
Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature.
Effect of angiogenesis inhibitor SU6668 in combination with 5-Fu on liver metastasis from transplantation tumors of human colorectal cancer in nude mice.
Effect of angiogenesis inhibitor TNP-470 on the progression of human gastric cancer xenotransplanted into nude mice.
Effect of bevacizumab treatment on p-boronophenylalanine distribution in murine tumor.
Effect of retroviral endostatin gene transfer on subcutaneous and intraperitoneal growth of murine tumors.
Effect of tetramethylpyrazine combined with cisplatin on VEGF, KLF4 and ADAMTS1 in Lewis lung cancer mice.
Effect of TNP-470 (AGM-1470) on the growth of rat rhabdomyosarcoma tumors of different sizes.
Effectiveness of the angiogenesis inhibitor TNP-470 in reducing the growth of human neuroblastoma in nude mice inversely correlates with tumor burden.
Effects of difluoromethylornithine on growth inhibition and apoptosis in human cervical epithelial and cancerous cell lines.
Effects of Linomide on growth and metastasis of implanted human gastric cancer in nude mice.
Efficacy and safety of apatinib as third- or further-line therapy for patients with advanced NSCLC: a retrospective study.
Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series.
Electrotransfer of gene encoding endostatin into normal and neoplastic mouse tissues: inhibition of primary tumor growth and metastatic spread.
Elevated levels of urine angiostatin and plasminogen/plasmin in cancer patients.
Endogenous angiogenesis inhibitor blocks tumor growth via direct and indirect effects on tumor microenvironment.
Endostatin-cytosine deaminase fusion protein suppresses tumor growth by targeting neovascular endothelial cells.
Enhanced anti-angiogenesis and anti-tumor activity of endostatin by chemical modification with polyethylene glycol and low molecular weight heparin.
Enhanced antiangiogenic therapy with antibody-collagen XVIII NC1 domain fusion proteins engineered to exploit matrix remodeling events.
Enhanced suppression of prostate tumor growth by combining C-CAM1 gene therapy and angiogenesis inhibitor TNP-470.
Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470) and cytotoxic agents in mice.
Enhanced Therapeutic Effect by Combination of Tumor-Targeting Salmonella and Endostatin in Murine Melanoma Model.
Enhancement of the effect of an angiogenesis inhibitor on murine tumors by hyperthermia.
Epigenetic silencing of triple negative breast cancer hallmarks by Withaferin A.
Eponemycin, a novel antibiotic, is a highly powerful angiogenesis inhibitor.
Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: A potential clinical application of angiogenesis inhibitors.
Expression and Clinical Significance of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and a Disintegrin and Metalloproteinase with Thrombospondin Type 1 Motif 1 (ADAMTS1) in Post-Kidney-Transplant Bladder Tumors.
Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases.
Expression of brain-specific angiogenesis inhibitor 1 is inversely correlated with pathological grade, angiogenesis and peritumoral brain edema in human astrocytomas.
Expression of CD34 and Maspin in ameloblastoma from a West African subpopulation.
Expression of METH-1 and METH-2 in pancreatic cancer.
Expression of the human fast-twitch skeletal muscle troponin I cDNA in a human ovarian carcinoma suppresses tumor growth.
Expression of the non-glycosylated kringle domain of tissue type plasminogen activator in Pichia and its anti-endothelial cell activity.
Extracellular Protease ADAMTS1 Is Required at Early Stages of Human Uveal Melanoma Development by Inducing Stemness and Endothelial-Like Features on Tumor Cells.
Features of microvessel density (MVD) and angiogenesis inhibitors in therapeutic approach of hepatocellular carcinoma (HCC).
Fibulin-1 is down-regulated through promoter hypermethylation and suppresses tumor progression in renal cell carcinoma.
Fibulin-1 is epigenetically down-regulated and related with bladder cancer recurrence.
Frequent administration of angiogenesis inhibitor TNP-470 (AGM-1470) at an optimal biological dose inhibits tumor growth and metastasis of metastatic human transitional cell carcinoma in the urinary bladder.
Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team.
Functionalized heparin-protamine based self-assembled nanocomplex for efficient anti-angiogenic therapy.
Functions of Thrombospondin-1 in the Tumor Microenvironment.
Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy.
Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers.
Gene therapy-mediated expression by tumor cells of the angiogenesis inhibitor flk-1 results in inhibition of neuroblastoma growth in vivo.
Gene transfer of NK4, an angiogenesis inhibitor, induces CT26 tumor regression via tumor-specific T lymphocyte activation.
Genetic analysis of high-metastatic clone of RCT sarcoma in mice, and its growth regression in vivo in response to angiogenesis inhibitor TNP-470.
Genetic inactivation of ADAMTS15 metalloprotease in human colorectal cancer.
Genetic landscape of a case of extraovarian peritoneal serous papillary carcinoma.
Genomic predictors of chemotherapy efficacy in advanced or recurrent gastric cancer in the GC0301/TOP002 phase III clinical trial.
Growth inhibition of liver metastases by the anti-angiogenic drug TNP-470.
Growth suppression of cervical carcinoma by pigment epithelium-derived factor via anti-angiogenesis.
HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice.
HNF4 alpha orchestrates a set of 14 genes to down-regulate cell proliferation in kidney cells.
Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells.
Hypoxia-inducible factor-1 inhibition in combination with temozolomide treatment exhibits robust antitumor efficacy in vivo.
Identification and characterization of the biosynthetic gene cluster of thiolutin, a tumor angiogenesis inhibitor, in Saccharothrix algeriensis NRRL B-24137.
Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance).
Identification of a novel tumor angiogenesis inhibitor targeting Shh/Gli1 signaling pathway in Non-small cell lung cancer.
Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor activity.
IL6-STAT3-HIF SIGNALLING AND THERAPEUTIC RESPONSE TO THE ANGIOGENESIS INHIBITOR, SUNITINIB, IN OVARIAN CLEAR CELL CANCER.
Immunoregulatory roles of versican proteolysis in the myeloma microenvironment.
Impact of tumor blood flow modulation on tumor sensitivity to the bioreductive drug banoxantrone.
Impaired coronary flow reserve in metastatic cancer patients treated with sunitinib.
Importance of vascular endothelial growth factor A in the progression of experimental neuroblastoma.
In silico characterization of the interaction between LSKL peptide, a LAP-TGF-beta derived peptide, and ADAMTS1.
In vitro and in vivo stimulation of the murine immune system by AGM-1470, a potent angiogenesis inhibitor.
In vitro and in vivo study of hydralazine, a potential anti-angiogenic agent.
In vitro effects of meloxicam on metabolism in articular chondrocytes from dogs with naturally occurring osteoarthritis.
In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects.
In Vivo Monitoring of Angiogenesis Inhibitory Treatment Effects by Dynamic Contrast-Enhanced Computed Tomography in a Xenograft Tumor Model.
Incidence and clinical implication of tumor cavitation in patients with advanced non-small cell lung cancer induced by Endostar, an angiogenesis inhibitor.
Increased mRNA expression of ADAMs in renal cell carcinoma and their association with clinical outcome.
Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis.
Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis.
Influence of the site of human gallbladder xenograft (Mz-ChA-1) on angiogenesis at the distant site.
Inhibition of ADAMTS1 Expression by Lentiviral CRISPR/Cas9 Gene Editing Technology.
Inhibition of angiogenesis.
Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4.
Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity.
Inhibition of hepatic metastasis in mice treated with cell-binding domain of human fibronectin and angiogenesis inhibitor TNP-470.
Inhibition of tumor growth and metastasis by angiogenesis inhibitor TNP-470 on breast cancer cell lines in vitro and in vivo.
Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470; AGM-1470).
Inhibition of tumor growth and microvascular angiogenesis by the potent angiogenesis inhibitor, TNP-470, in rats.
Inhibition of tumor growth by antibody to ADAMTS1 in mouse xenografts of breast cancer.
Inhibition of tumor growth through suppression of angiogenesis by brain-specific angiogenesis inhibitor 1 gene transfer in murine renal cell carcinoma.
Inhibition of tumor-associated ?v?3 integrin regulates the angiogenic switch by enhancing expression of IGFBP-4 leading to reduced melanoma growth and angiogenesis in vivo.
Inhibition of xenografted human melanoma growth and prevention of metastasis development by dual antiangiogenic/antitumor activities of pigment epithelium-derived factor.
Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo.
Inhibitory effect of endostar on specific angiogenesis induced by human hepatocellular carcinoma.
Inhibitory Effect of the Angiogenesis Inhibitor O-(Chloroacetyl-carbamoyl)fumagillol(TNP-470) on Tumor Growth and Metastasis of Murine Mammary Tumor Cell Line (JYG-B)Inoculated in Female Nude Mice.
Inhibitory effect of the angiogenesis inhibitor TNP-470 on tumor growth and metastasis in nude mice bearing human hepatocellular carcinoma.
Inhibitory effect of TNP-470 on hepatic metastasis of mouse neuroblastoma.
Inhibitory effects of epigallocatechin-3 gallate, a polyphenol in green tea, on tumor-associated endothelial cells and endothelial progenitor cells.
Inhibitory effects of roxithromycin on tumor angiogenesis, growth and metastasis of mouse B16 melanoma cells.
Initial testing of the multitargeted kinase inhibitor pazopanib by the pediatric preclinical testing program.
Interferon Alfa-2b for Recurrent and Metastatic Giant Cell Tumor of the Spine: Report of Two Cases.
Interferon-alpha as angiogenesis inhibitor: learning from tumor models.
Intra-tumor injection of an angiogenesis inhibitor, TNP-470, in rabbits bearing VX2 carcinoma of the tongue.
Intratumoral gene therapy of malignant brain tumor in a rat model with angiostatin delivered by adeno-associated viral (AAV) vector.
Isthmin is a novel secreted angiogenesis inhibitor that inhibits tumor growth in mice.
Kallistatin Suppresses Cell Proliferation and Invasion and Promotes Apoptosis in Cervical Cancer Through Blocking NF-?B Signaling.
Kallistatin, a novel anti-angiogenesis agent, inhibits angiogenesis via inhibition of the NF-?B signaling pathway.
KR-31831, a new synthetic anti-ischemic agent, inhibits in vivo and in vitro angiogenesis.
Kringle structures and antiangiogenesis.
Lack of antitumor activity of recombinant endostatin in a human neuroblastoma xenograft model.
Laminin binding to the calreticulin fragment vasostatin regulates endothelial cell function.
Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage.
Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A.
lncRNA/mRNA profiling of endometriosis rat uterine tissues during the implantation window.
Long non-coding RNA ADAMTS9-AS2 inhibits liver cancer cell proliferation, migration and invasion.
Long-term survival of a patient with small-cell lung cancer (SCLC) following treatment with thalidomide and combination chemotherapy.
Loss of Forkhead Box O3 Facilitates Inflammatory Colon Cancer: Transcriptome Profiling of the Immune Landscape and Novel Targets.
Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma.
Maspin expression in normal skin and usual cutaneous carcinomas.
MCT-1 oncogene contributes to increased in vivo tumorigenicity of MCF7 cells by promotion of angiogenesis and inhibition of apoptosis.
Melatonin as an angiogenesis inhibitor to combat cancer: Mechanistic evidence.
Melatonin-triggered post-transcriptional and post-translational modifications of ADAMTS1 coordinately retard tumorigenesis and metastasis of renal cell carcinoma.
Metabolism of the tumor angiogenesis inhibitor 4-(N-(S-Glutathionylacetyl)amino)phenylarsonous acid.
Metastatic dormancy imposed by the primary tumor: does it exist in humans?
Methylation and silencing of the Thrombospondin-1 promoter in human cancer.
Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma.
MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer.
Moderate antiangiogenic activity by local, transgenic expression of endostatin in Rip1Tag2 transgenic mice.
Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib.
Molecular mechanisms and therapeutic development of angiogenesis inhibitors.
Molecular targeted therapy in ovarian cancer: what is on the horizon?
Mouse endostatin inhibits the formation of lung and liver metastases.
MRI characterization of tumors and grading angiogenesis using macromolecular contrast media: status report.
Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma.
Myopericytoma arising from myopericytosis-a hitherto unrecognized entity within the lung.
N-terminal fragment of the anti-angiogenic human endostatin binds copper(II) with very high affinity.
Natural Products as Anticancer Agents.
New Insights Into Implementation of Mesenchymal Stem Cells in Cancer Therapy: Prospects for Anti-angiogenesis Treatment.
NK4, an HGF antagonist, prevents hematogenous pulmonary metastasis by inhibiting adhesion of CT26 cells to endothelial cells.
NOL7 is a nucleolar candidate tumor suppressor gene in cervical cancer that modulates the angiogenic phenotype.
Nutriproteomic Analysis of Hwangmaemok-Induced Antiangiogenic Effect Using Antibody-Arrayed Protein Chip Assay.
Oral delivery of a potent anti-angiogenic heparin conjugate by chemical conjugation and physical complexation using deoxycholic acid.
Original insights on thrombospondin-1-related antireceptor strategies in cancer.
Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven.
Overexpression of MBD2 in Glioblastoma Maintains Epigenetic Silencing and Inhibits the Anti-Angiogenic Function of the Tumor Suppressor Gene BAI1.
Overexpression of the p53-inducible brain-specific angiogenesis inhibitor 1 suppresses efficiently tumour angiogenesis.
Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas.
Parathyroid hormone-related peptide is a naturally occurring, protein kinase A-dependent angiogenesis inhibitor.
PEDF inhibits growth of retinoblastoma by anti-angiogenic activity.
Peptide Micelle-Mediated Delivery of Tissue-Specific Suicide Gene and Combined Therapy with Avastin in a Glioblastoma Model.
Peritumoral injection of adenovirus vector expressing NK4 combined with gemcitabine treatment suppresses growth and metastasis of human pancreatic cancer cells implanted orthotopically in nude mice and prolongs survival.
Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models.
Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470.
Pharmacokinetic and pharmacodynamic study of intratumoral injection of an adenovirus encoding endostatin in patients with advanced tumors.
Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors.
Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer.
Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors.
Phase I trial of pazopanib in patients with advanced cancer.
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors.
Pigment epithelium-derived factor as an anticancer drug and new treatment methods following the discovery of its receptors: a patent perspective.
Piperine, a dietary phytochemical, inhibits angiogenesis.
Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib.
Platelet-derived thrombospondin-1 (TSP-1) is a critical negative regulator and potential biomarker of angiogenesis.
PNU-145156E, a novel angiogenesis inhibitor, in patients with solid tumors: a phase I and pharmacokinetic study.
Post-transcriptional gene regulation by HuR promotes a more tumorigenic phenotype.
Postoperative progression of pulmonary metastasis in osteosarcoma.
Potent inhibition of angiogenesis by wortmannin, a fungal metabolite.
Potential novel role of bevacizumab in glioblastoma and cervical cancer.
Potentiation of anti-angiogenic activity of heparin by blocking the ATIII-interacting pentasaccharide unit and increasing net anionic charge.
Potentiation of platinum antitumor effects in human lung tumor xenografts by the angiogenesis inhibitor squalamine: effects on tumor neovascularization.
PPARalpha deficiency in inflammatory cells suppresses tumor growth.
Preparation, characterization, in vitro and in vivo anti-tumor effect of thalidomide nanoparticles on lung cancer.
Prevention of hepatic and peritoneal metastases by the angiogenesis inhibitor fr-118487 after removal of growing tumor in mice.
Production of interleukin-10 by alveolar macrophages from lung cancer patients.
Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood.
Proteolytic inactivation of anti-angiogenic vasohibin-1 by cancer cells.
Pterostilbene carboxaldehyde thiosemicarbazone, a resveratrol derivative inhibits 17?-Estradiol induced cell migration and proliferation in HUVECs.
rAAV-mediated long-term liver-generated expression of an angiogenesis inhibitor can restrict renal tumor growth in mice.
rAdinbitor, a disintegrin from Agkistrodon halys brevicaudus stejneger, inhibits tumorigenicity of hepatocarcinoma via enhanced anti-angiogenesis and immunocompetence.
Randomized, Placebo-Controlled, Phase III Study of Oxaliplatin, Fluorouracil, and Leucovorin With or Without PTK787/ZK 222584 in Patients With Previously Treated Metastatic Colorectal Adenocarcinoma.
Recent developments in mushrooms as anti-cancer therapeutics: a review.
Recombinant human endostatin improves anti-tumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma.
Recombinant human maspin inhibits high glucose-induced oxidative stress and angiogenesis of human retinal microvascular endothelial cells via PI3K/AKT pathway.
Regression of metastatic liver tumors in rats treated with angiogenesis inhibitor TNP-470: occurrence of apoptosis and necrosis.
Regulation of tumor angiogenesis by thrombospondin-1.
Response of Rat Prostate and Lung Tumors to Ionizing Radiation Combined with the Angiogenesis Inhibitor AMCA.
Response to antiangiogenesis therapy in a patient with advanced adult-type testicular granulosa cell tumor.
Retroviral vector-producer cell mediated angiogenesis inhibition restricts neuroblastoma growth in vivo.
RGD-Modified Angiogenesis Inhibitor HM-3 Dose: Dual Function during Cancer Treatment.
Rifampicin as an oral angiogenesis inhibitor targeting hepatic cancers.
Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials.
Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients.
Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.
Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer.
Secretion of phosphoglycerate kinase from tumour cells is controlled by oxygen-sensing hydroxylases.
Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models.
Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype.
Serum levels of endostatin, vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in patients with acute myocardial infarction undergoing early reperfusion therapy.
Short pigment epithelial-derived factor-derived peptide inhibits angiogenesis and tumor growth.
Sigma receptor-mediated targeted delivery of anti-angiogenic multifunctional nanodrugs for combination tumor therapy.
Significant inhibition of endothelial cell growth in tumor vasculature by an angiogenesis inhibitor, TNP-470 (AGM-1470).
Simple Host-Guest Assembly for High-Resolution Magnetic Resonance Imaging of Microvasculature.
SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix.
Spectral Computed Tomographic Parameters Predict the Therapeutic Efficacy and Overall Survival of the Angiogenesis Inhibitor AL3818 in Hepatic Lesions: Preliminary Animal Study.
Stem-like tumor cells involved in heterogeneous vasculogenesis in breast cancer.
Stroma-derived but not tumor ADAMTS1 is a main driver of tumor growth and metastasis.
Structure and inhibitory effects on angiogenesis and tumor development of a new vascular endothelial growth inhibitor.
Suppression of lung tumor growth and metastasis in mice by adeno-associated virus-mediated expression of vasostatin.
Suppression of tumor growth and downregulation of platelet-derived endothelial cell growth factor / thymidine phosphorylase in tumor cells by angiogenesis inhibitor TNP-470.
Synergistic antitumor effect of an angiogenesis inhibitor (TNP-470) and tumor necrosis factor in mice.
Synergistic effect of the angiogenesis inhibitor TNP-470 and tumor necrosis factor (TNF) on Bomirski Ab melanoma in hamsters.
Synthesis and cytotoxic studies of novel 5-phenylisatin derivatives and their anti-migration and anti-angiogenic evaluation.
Synthesis and preliminary evaluation of 5,7-dimethyl-2-aryl-3H-pyrrolizin-3-ones as angiogenesis inhibitors.
Systemic NK4 gene therapy inhibits tumor growth and metastasis of melanoma and lung carcinoma in syngeneic mouse tumor models.
TARBP2 promotes tumor angiogenesis and metastasis by destabilizing antiangiogenic factor mRNAs.
Targeting angiogenesis and HGF function using an adenoviral vector expressing the HGF antagonist NK4 for cancer therapy.
Targeting angiogenesis inhibits tumor infiltration and expression of the pro-invasive protein SPARC.
Targeting the HER1/EGFR receptor to improve outcomes in non-small-cell lung cancer.
Targeting thymidine phosphorylase inhibition in human colorectal cancer xenografts.
Technology evaluation: ABT-510, Abbott.
Telomerase activity correlates with growth of transplantable osteosarcomas in rats treated with cis-diammine dichloroplatinum or the angiogenesis inhibitor AGM-1470.
Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment.
Thalidomide-induced bronchiolitis obliterans organizing pneumonia in a patient with multiple myeloma.
Thalidomide-induced organizing pneumonia.
The 2005 Leon I. Goldberg Young Investigator Award Lecture: Development of thalidomide as an angiogenesis inhibitor for the treatment of androgen-independent prostate cancer.
The ADAMTS1 protease gene is required for mammary tumor growth and metastasis.
The angiogenesis inhibitor TNP-470 reduces the growth rate of human neuroblastoma in nude rats.
The angiogenesis inhibitor vasostatin does not impair wound healing at tumor-inhibiting doses.
The antitumor effect of a novel angiogenesis inhibitor (an octahydronaphthalene derivative) targeting both VEGF receptor and NF-?B pathway.
The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells.
The bisphosphonate, zoledronic acid reduces experimental neuroblastoma growth by interfering with tumor angiogenesis.
The cleavage of semaphorin 3C induced by ADAMTS1 promotes cell migration.
The combination of antiangiogenic agents to inhibit primary tumor growth and metastasis.
The diagnostic significance of circulating lncRNA ADAMTS9-AS2 tumor biomarker in non-small cell lung cancer among the Egyptian population.
The effect of angiogenesis inhibitor TNP-470 on the blood vessels of the lungs, kidneys and livers of treated hamsters.
The effect of TNP-470 on cell proliferation and urokinase-type plasminogen activator and its inhibitor in human lung cancer cell lines.
The effects of hypericin on ADAMTS and p53 gene expression in MCF-7 breast cancer cells.
The increase of apoptosis and the decrease of proliferation by angiogenesis inhibitor in rat mammary tumors.
The influence of angiogenesis inhibitor AGM-1470 on immune system status and tumor growth in vitro.
The metalloproteinase ADAMTS1: A comprehensive review of its role in tumorigenic and metastatic pathways.
The multi-step process of human skin carcinogenesis: a role for p53, cyclin D1, hTERT, p16, and TSP-1.
The prostatic environment suppresses growth of androgen-independent prostate cancer xenografts: An effect influenced by testosterone.
The Role of E-Cadherin/?-Catenin in Hydroxysafflor Yellow A Inhibiting Adhesion, Invasion, Migration and Lung Metastasis of Hepatoma Cells.
The selective class III/V receptor tyrosine kinase inhibitor SU11657 inhibits tumor growth and angiogenesis in experimental neuroblastomas grown in mice.
The suppression of postoperative liver metastasis caused by the continuous intraportal infusion of angiogenesis inhibitor FR-118487 in a rabbit colon cancer model.
Therapeutic Application of Brain-Specific Angiogenesis Inhibitor 1 for Cancer Therapy.
Therapeutic effect and side effects of Bevacizumab combined with Irinotecan in the treatment of paediatric intracranial tumours: Meta-analysis and Systematic Review.
Therapeutic effect of TNP-470 on spontaneous liver metastasis of colon tumors in the rabbit.
TIP30 directly binds p53 tumor suppressor protein in vitro.
Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin.
TNP-470 fails to block the onset of angiogenesis and early tumor establishment in an intravital minimal disease model.
TNP-470 inhibits collateralization to complement the anti-tumour effect of hepatic artery ligation.
TNP-470 Reduces Glioblastoma Angiogenesis in Three Dimensional GelMA Microwell Platform.
TNP-470: an angiogenesis inhibitor in clinical development for cancer.
Tranilast inhibits the proliferation, chemotaxis and tube formation of human microvascular endothelial cells in vitro and angiogenesis in vivo.
Transcatheter Arterial Embolization Containing Donafenib Induces Anti-Angiogenesis and Tumoricidal CD8+ T-Cell Infiltration in Rabbit VX2 Liver Tumor.
Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype.
Treatment of metastatic liver tumors by intermittent repetitive injection of an angiogenesis inhibitor using an implantable port system in a rabbit model.
Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.
Tumor angiogenesis promoted by ex vivo differentiated endothelial progenitor cells is effectively inhibited by an angiogenesis inhibitor, TK1-2.
Tumor anti-angiogenic gene therapy with microencapsulated recombinant CHO cells.
Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer.
Tumor endothelial cell targeted cyclic RGD-modified heparin derivative: inhibition of angiogenesis and tumor growth.
Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.
Tumor growth inhibition and regression induced by photothermal vascular targeting and angiogenesis inhibitor retinoic acid.
Tumor growth inhibitory effect of ADAMTS1 is accompanied by the inhibition of tumor angiogenesis.
Tumor Progression of Non-Small Cell Lung Cancer Controlled by Albumin and Micellar Nanoparticles of Itraconazole, a Multitarget Angiogenesis Inhibitor.
Tumor suppression through angiogenesis inhibition by SUIT-2 pancreatic cancer cells genetically engineered to secrete NK4.
Two functional epitopes of pigment epithelial-derived factor block angiogenesis and induce differentiation in prostate cancer.
Upregulation of endogenous angiogenesis inhibitors: a mechanism of action of metronomic chemotherapy.
Vascular endothelial growth factor and DPC4 predict adjuvant therapy outcomes in resected pancreatic cancer.
Vascular permeability during antiangiogenesis treatment: MR imaging assay results as biomarker for subsequent tumor growth in rats.
Vasohibin-1 expression in endothelium of tumor blood vessels regulates angiogenesis.
Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth.
VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside.
VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo.
WSS25 inhibits growth of xenografted hepatocellular cancer cells in nude mice by disrupting angiogenesis via blocking bone morphogenetic protein (BMP)/Smad/Id1 signaling.
[A man with blisters on hand and feet].
[Advances in the study of mechanisms of the tumor angiogenesis inhibitors]
[An experimental study of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of Lewis lung carcinoma]
[Anticancer drugs under pressure].
[Application of bevacizumab on metastatic breast cancer].
[Cancer therapy targeting tumor-induced neovascularization]
[Cloning and antitumor activity of angiogenesis inhibitor HIAF-1]
[Construction and activity of recombinant adeno-associated virus expressing vasostatin]
[Effect of angiogenesis inhibitor Rg3 on the growth and metastasis of gastric cancer in SCID mice]
[Effect of angiogenesis inhibitor SU6668 on the growth and metastasis of gastric cancer in SCID mice]
[Experimental study of the effect of angiogenesis inhibitor TNP-470 on the growth and metastasis of gastric cancer in vivo]
[Expression of biologically active recombinant arresten in Nicotiana tabacum]
[Gastrectomy for Bleeding Gastric Cancer During Ramucirumab plus Paclitaxel Therapy-A Case Report].
[Inhibition of growth and metastases of human colon cancer xenograft in nude mice by angiogenesis inhibitor endostatin]
[Inhibition of growth and metastasis of human gastric cancer implanted in nude mice by the angiogenesis inhibitor endostatin]
[Inhibition of liver metastases in rabbits by arterial infusion of angiogenesis inhibitor, TNP-470]
[Inhibitory effect of fumagillol combined with cyclophosphamide on metastasis of lung adenocarcinoma cell line LA795 xenograft in mice]
[Interests in angiogenesis inhibitor drugs approved for the treatment of cancers]
[Mechanism of regression of metastatic liver tumors in rats treated with angiogenesis inhibitor with special reference to apoptosis]
[Suppression of peritoneal implantation by NK4 and its mechanisms]
[The angiogenesis inhibitor vasostatin. In tumor inhibiting doses there is no impaired wound healing in the mouse model]
[Vascular and renal effects of anti-angiogenic therapy]
Nephrotic Syndrome
Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib.
Neuroblastoma
Angiogenesis can be reduced without significant reduction of tumor growth.
Autocrine expression of both endostatin and green fluorescent protein provides a synergistic antitumor effect in a murine neuroblastoma model.
Effectiveness of the angiogenesis inhibitor TNP-470 in reducing the growth of human neuroblastoma in nude mice inversely correlates with tumor burden.
Endostatin-mediated concomitant resistance in neuroblastoma.
Gene therapy-mediated expression by tumor cells of the angiogenesis inhibitor flk-1 results in inhibition of neuroblastoma growth in vivo.
Importance of vascular endothelial growth factor A in the progression of experimental neuroblastoma.
In vivo evaluation of microspheres containing the angiogenesis inhibitor, TNP-470, and the metastasis suppression with liver metastatic model implanted neuroblastoma.
Inhibition of angiogenesis induces chromaffin differentiation and apoptosis in neuroblastoma.
Inhibitory effect of TNP-470 on hepatic metastasis of mouse neuroblastoma.
Lack of antitumor activity of recombinant endostatin in a human neuroblastoma xenograft model.
Longterm recombinant adeno-associated, virus-mediated, liver-generated expression of an angiogenesis inhibitor improves survival in mice with disseminated neuroblastoma.
Retroviral vector-producer cell mediated angiogenesis inhibition restricts neuroblastoma growth in vivo.
The angiogenesis inhibitor tnp-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease.
The angiogenesis inhibitor TNP-470 reduces the growth rate of human neuroblastoma in nude rats.
The N-myc oncogene in human neuroblastoma cells: down-regulation of an angiogenesis inhibitor identified as activin A.
The selective class III/V receptor tyrosine kinase inhibitor SU11657 inhibits tumor growth and angiogenesis in experimental neuroblastomas grown in mice.
Neurodegenerative Diseases
Genome-wide association study of cerebrospinal fluid neurofilament light levels in non-demented elders.
Genomic structure and alternative splicing of the insulin receptor tyrosine kinase substrate of 53-kDa protein.
Neuroendocrine Tumors
Synthesis and preliminary evaluation of 5,7-dimethyl-2-aryl-3H-pyrrolizin-3-ones as angiogenesis inhibitors.
Neurofibromatoses
Association of Rapidly Progressive Moyamoya Syndrome With Bevacizumab Treatment for Glioblastoma in a Child With Neurofibromatosis Type 1.
Neurofibromatosis 1
Association of Rapidly Progressive Moyamoya Syndrome With Bevacizumab Treatment for Glioblastoma in a Child With Neurofibromatosis Type 1.
Non-alcoholic Fatty Liver Disease
The Angiogenesis Inhibitor ALS-L1023 from Lemon-Balm Leaves Attenuates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease through Regulating the Visceral Adipose-Tissue Function.
Obesity
A glucocorticoid- and diet-responsive pathway toggles adipocyte precursor cell activity in vivo.
A multitarget angiogenesis inhibitor, CTT peptide-endostatin mimic-kringle 5, prevents diet-induced obesity.
Angiogenesis inhibitor, TNP-470, prevents diet-induced and genetic obesity in mice.
Assessment of the anti-obesity effects of the TNP-470 analog, CKD-732.
The lemon balm extract ALS-L1023 inhibits obesity and nonalcoholic fatty liver disease in female ovariectomized mice.
Oligodendroglioma
Microvesicles shed by oligodendroglioma cells and rheumatoid synovial fibroblasts contain aggrecanase activity.
Osteoarthritis
Elucidation of the Mechanism by Which a ADAMTS5 Gene MicroRNA-Binding Site Single Nucleotide Polymorphism Affects the Risk of Osteoarthritis.
Intraarticular gene transfer of thrombospondin-1 suppresses the disease progression of experimental osteoarthritis.
Missense single nucleotide polymorphism of the ADAM12 gene is associated with radiographic knee osteoarthritis in middle-aged Estonian cohort.
The role of ADAMTS genes in the end stage of hip osteoarthritis.
Osteoarthritis, Knee
Elucidation of the Mechanism by Which a ADAMTS5 Gene MicroRNA-Binding Site Single Nucleotide Polymorphism Affects the Risk of Osteoarthritis.
Osteonecrosis
Delayed Healing of Tooth Extraction Sockets with Ramucirumab Use.
Osteosarcoma
Delay in administration of CDDP until completion of AGM-1470 treatment enhances antimetastatic and antitumor effects.
Efficacy of the angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (AGM-1470) on osteosarcoma growth and lung metastasis in rats.
Suppression of pulmonary metastasis by angiogenesis inhibitor TNP-470 in murine osteosarcoma.
Telomerase activity correlates with growth of transplantable osteosarcomas in rats treated with cis-diammine dichloroplatinum or the angiogenesis inhibitor AGM-1470.
Ovarian Diseases
Blood and lymphatic vasculature in the ovary: development, function and disease.
Ovarian Neoplasms
Advances in anti-angiogenic agents for ovarian cancer treatment: The role of trebananib (AMG 386).
Cardamonin Inhibits Angiogenesis by mTOR Downregulation in SKOV3 Cells.
Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo.
Long non-coding RNA ADAMTS9-AS2 inhibits liver cancer cell proliferation, migration and invasion.
Phase I trials of dexrazoxane and other potential applications for the agent.
The C-terminus of IGFBP-5 suppresses tumor growth by inhibiting angiogenesis.
The inhibitory effect of hypoxic cytotoxin on the expansion of cancer stem cells in ovarian cancer.
[Experimental therapy with angiogenesis inhibitor TNP-470 on human ovarian cancer transplanted subcutaniously in nude mice]
Overweight
Angiogenic factors are elevated in overweight and obese individuals.
Pancreatic Neoplasms
A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer.
Angiogenesis inhibitor TNP-470 reduces human pancreatic cancer growth.
Antiangiogenic treatment with the three thrombospondin-1 type 1 repeats recombinant protein in an orthotopic human pancreatic cancer model.
Antiangiogenic versus cytotoxic therapeutic approaches in a mouse model of pancreatic cancer: an experimental study with a multitarget tyrosine kinase inhibitor (sunitinib), gemcitabine and radiotherapy.
Cell-Free DNA Methylation: The New Frontiers of Pancreatic Cancer Biomarkers' Discovery.
Expression of METH-1 and METH-2 in pancreatic cancer.
Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma.
Multi-Omics Analysis of Anlotinib in Pancreatic Cancer and Development of an Anlotinib-Related Prognostic Signature.
Novel Methylation Biomarker Panel for the Early Detection of Pancreatic Cancer.
Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood.
Survival benefit of KRN7000 immune therapy in combination with TNP470 in hamster liver metastasis model of pancreatic cancer.
Traditional Chinese medicine Astragalus polysaccharide enhanced antitumor effects of the angiogenesis inhibitor apatinib in pancreatic cancer cells on proliferation, invasiveness, and apoptosis.
Troponin I peptide (Glu94-Leu123), a cartilage-derived angiogenesis inhibitor: in vitro and in vivo effects on human endothelial cells and on pancreatic cancer.
Tumor suppression through angiogenesis inhibition by SUIT-2 pancreatic cancer cells genetically engineered to secrete NK4.
Peripheral Arterial Disease
Critical Roles of Cold Shock Domain Protein A as an Endogenous Angiogenesis Inhibitor in Skeletal Muscle.
Peritoneal Fibrosis
A novel angiogenesis inhibitor, sunitinib malate, in encapsulating peritoneal sclerosis.
Antiangiogenic and antifibrotic gene therapy in a chronic infusion model of peritoneal dialysis in rats.
TNP-470, an angiogenesis inhibitor, suppresses the progression of peritoneal fibrosis in mouse experimental model.
Peritoneal Neoplasms
Effects of the angiogenesis inhibitor angiostatin on the growth of CC531 colon carcinoma cells in vitro and in a laparoscopic animal model of peritoneal carcinomatosis.
Peritonitis
Therapeutic effects of the angiogenesis inhibitor TNP-470 against carcinomatous peritonitis in mice.
[Therapeutic efficiency of an angiogenesis inhibitor, TNP-470, against carcinomatous peritonitis in rodents]
[Therapy of carcinomatous peritonitis by the angiogenesis inhibitor TNP-470 in mice: analysis of timing and doses for intraperitoneal administration]
Pituitary Neoplasms
Effect of angiogenesis inhibitor TNP-470 on vascular formation in pituitary tumors induced by estrogen in rats.
Polycystic Ovary Syndrome
Clinical significance of ADAMTS1, ADAMTS5, ADAMTS9 aggrecanases and IL-17A, IL-23, IL-33 cytokines in polycystic ovary syndrome.
Expression Level of ADAMTS1 in Granulosa Cells of PCOS Patients Is Related to Granulosa Cell Function, Oocyte Quality, and Embryo Development.
Port-Wine Stain
Can the wound healing response of human skin be modulated after laser treatment and the effects of exposure extended? Implications on the combined use of the pulsed dye laser and a topical angiogenesis inhibitor for treatment of port wine stain birthmarks.
Pre-Eclampsia
Natural selection of FLT1 alleles and their association with malaria resistance in utero.
Suramin-restricted blood volume in the placenta of normal and diabetic rats is normalized by vitamin E treatment.
Thrombomodulin is upregulated in the kidneys of women with pre-eclampsia.
Primary Ovarian Insufficiency
Epistasis between IGF2R and ADAMTS19 polymorphisms associates with premature ovarian failure.
Interaction between thyroglobulin and ADAMTS16 in premature ovarian failure.
Prognathism
The ADAMTS1 Gene Is Associated with Familial Mandibular Prognathism.
Prostatic Neoplasms
A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer.
A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.
ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers.
ADAMTS1 alters blood vessel morphology and TSP1 levels in LNCaP and LNCaP-19 prostate tumors.
ADAMTS1, a putative anti-angiogenic factor, is decreased in human prostate cancer.
Angiogenesis inhibitor TNP-470 inhibits growth and metastasis of a hormone-independent rat prostatic carcinoma cell line.
Enhanced suppression of prostate tumor growth by combining C-CAM1 gene therapy and angiogenesis inhibitor TNP-470.
Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer.
Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study.
Relative cytotoxic potencies and cell death mechanisms of ?1 -adrenoceptor antagonists in prostate cancer cell lines.
Replication-incompetent gammaretroviral and lentiviral vector-based insertional mutagenesis screens identify prostate cancer progression genes.
SSeCKS/AKAP12 induces repulsion between human prostate cancer and microvessel endothelial cells through the activation of Semaphorin 3F.
Target to apoptosis: a hopeful weapon for prostate cancer.
The 2005 Leon I. Goldberg Young Investigator Award Lecture: Development of thalidomide as an angiogenesis inhibitor for the treatment of androgen-independent prostate cancer.
The effect of maltose tetrapalmitate (MTP) on prostate cancer growth in vivo and in vitro.
[Elucidating the molecular mechanism of prostate cancer progression under chronic hypoxia and development of the novel therapeutic approach].
Psoriasis
Candidate gene polymorphisms and risk of psoriasis: A pilot study.
Phase I trials of dexrazoxane and other potential applications for the agent.
Pulmonary Fibrosis
Endostatin, an angiogenesis inhibitor, ameliorates bleomycin-induced pulmonary fibrosis in rats.
Phase I trials of dexrazoxane and other potential applications for the agent.
Purpura, Thrombotic Thrombocytopenic
Amino acid residues Arg(659), Arg(660), and Tyr(661) in the spacer domain of ADAMTS13 are critical for cleavage of von Willebrand factor.
Retinal Neovascularization
Vascular endothelial growth factor upregulates expression of ADAMTS1 in endothelial cells through protein kinase C signaling.
Retinoblastoma
A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells.
Sarcoidosis
Differential transcriptomics in sarcoidosis lung and lymph node granulomas with comparisons to pathogen-specific granulomas.
Sarcoma
Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team.
Antitumor effect of TNP-470, an angiogenesis inhibitor, combined with ultrasound irradiation for human uterine sarcoma xenografts evaluated using contrast color Doppler ultrasound.
Efficacy and safety of anlotinib, a multikinase angiogenesis inhibitor, in combination with epirubicin in preclinical models of soft tissue sarcoma.
Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.
Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series.
Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization.
Fast and Straightforward Method for the Quantification of Pazopanib in Human Plasma Using LC-MS/MS.
Genetic analysis of high-metastatic clone of RCT sarcoma in mice, and its growth regression in vivo in response to angiogenesis inhibitor TNP-470.
Pazopanib in Metastatic Renal Cancer: A "Real-World" Experience at National Cancer Institute "Fondazione G. Pascale".
Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).
Pazopanib-Induced Severe Acute Pancreatitis.
Phase I Pharmacokinetic and Pharmacodynamic Study of Pazopanib in Children With Soft Tissue Sarcoma and Other Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report.
Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma.
Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients.
Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma.
Therapeutic Response of Soft Tissue Sarcoma With Novel SS18-POU5F1 Fusion: A Case Report.
Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma.
Sarcoma, Alveolar Soft Part
Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma.
Sarcoma, Ewing
ADAMTS1 contributes to the acquisition of an endothelial-like phenotype in plastic tumor cells.
Sarcoma, Kaposi
Angiogenesis inhibitor and Kaposi sarcoma.
Phase I trials of dexrazoxane and other potential applications for the agent.
Phase II AIDS Malignancy Consortium trial of topical halofuginone in AIDS-related Kaposi sarcoma.
Scleroderma, Systemic
Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis.
Sepsis
ANGIOGENESIS INHIBITOR ENDOSTATIN PROTECTS MICE WITH SEPSIS FROM MULTIPLE ORGAN DYSFUNCTION SYNDROME.
Spinal Cord Injuries
ADAMTS1, ADAMTS5, ADAMTS9 and aggrecanase-generated proteoglycan fragments are induced following spinal cord injury in mouse.
Squamous Cell Carcinoma of Head and Neck
Anti-tumor effect of radiation response by combined treatment with angiogenesis inhibitor, TNP-470, in oral squamous cell carcinoma.
Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study.
[Effect of Angiogenesis inhibitor (TNP-470) on the morphology of GNM cell line in vitro]
Stomach Neoplasms
Angiogenesis inhibitor, TNP-470, suppresses growth of peritoneal disseminating foci.
Anti-tumor effect of angiogenesis inhibitor TNP-470 and 5-FU combined therapy on human gastric cancer xenograft.
Bevacizumab followed by chemotherapy is potential therapy for gastric cancer.
Combination of the Tumor Angiogenesis Inhibitor Bevacizumab and Intratumoral Oncolytic Herpes Virus Injections as a Treatment Strategy for Human Gastric Cancers.
Differential expression of angiogenesis-related genes in human gastric cancers with and those without high-frequency microsatellite instability.
Downregulation of A disintegrin and metallopeptidase with thrombospondin motif type 1 by DNA hypermethylation in human gastric cancer.
Effect of angiogenesis inhibitor TNP-470 on the progression of human gastric cancer xenotransplanted into nude mice.
Effects of Linomide on growth and metastasis of implanted human gastric cancer in nude mice.
Expression of ADAMTS1 and its correlation with angiogenesis in primary gastric cancer and lymph node metastasis.
Suppression of tumor growth, invasion and angiogenesis of human gastric cancer by adenovirus-mediated expression of NK4.
Synergistic effect of oxymatrine and angiogenesis inhibitor NM-3 on modulating apoptosis in human gastric cancer cells.
[Effect of angiogenesis inhibitor Rg3 on the growth and metastasis of gastric cancer in SCID mice]
[Effect of angiogenesis inhibitor SU6668 on the growth and metastasis of gastric cancer in SCID mice]
[Experimental study of the effect of angiogenesis inhibitor TNP-470 on the growth and metastasis of gastric cancer in vivo]
[Inhibition of growth and metastasis of human gastric cancer implanted in nude mice by the angiogenesis inhibitor endostatin]
Stomatitis, Aphthous
High-level expression of vascular endothelial growth factor and its receptors in an aphthous ulcer.
Synovitis
Angiogenesis and the persistence of inflammation in a rat model of proliferative synovitis.
Thrombocytopenia
Megakaryocytes require thrombospondin-2 for normal platelet formation and function.
Thromboembolism
A case report of endorectal displacement of a right ureteral stent following radiochemotherapy and Bevacizumab.
Thrombosis
Portal Vein Thrombosis in Metastatic Colorectal Cancer During FOLFIRI-bevacizumab Chemotherapy Successfully Treated with Apixaban.
Temporal and pharmacological characterization of angiostatin release and generation by human platelets: implications for endothelial cell migration.
Thymoma
Motesanib diphosphate (AMG 706), an oral angiogenesis inhibitor, demonstrates clinical efficacy in advanced thymoma.
Thyroid Cancer, Papillary
Role of gene expression profiling in defining indeterminate thyroid nodules in addition to BRAF analysis.
Thyroid Carcinoma, Anaplastic
Therapeutic efficacy of the angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470) for human anaplastic thyroid carcinoma in nude mice.
Thyroid Neoplasms
Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models.
Triple Negative Breast Neoplasms
A Systems Pharmacology Approach Uncovers Wogonoside as an Angiogenesis Inhibitor of Triple-Negative Breast Cancer by Targeting Hedgehog Signaling.
Current Issues of Targeted Therapy in Metastatic Triple-Negative Breast Cancer.
Tuberous Sclerosis
Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors.
Urinary Bladder Neoplasms
Antitumour effects of the angiogenesis inhibitor AGM-1470 on rat urinary bladder tumours induced by N-butyl-N-(4-hydroxybutyl) nitrosamine.
Comparative study of apoptotic antitumor effect between angiogenesis inhibitor AGM-1470 and MVAC chemotherapy on rat urinary bladder cancer.
Expression and Clinical Significance of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and a Disintegrin and Metalloproteinase with Thrombospondin Type 1 Motif 1 (ADAMTS1) in Post-Kidney-Transplant Bladder Tumors.
Fibulin-1 is epigenetically down-regulated and related with bladder cancer recurrence.
Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response.
Uterine Cervical Neoplasms
A model for co-expression pattern analysis of genes implicated in angiogenesis and tumour cell invasion in cervical cancer.
Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470.
Prevalence of Angiogenesis, Proliferation, and Apoptosis Markers of Cervical Cancer and Their Correlation with Clinicopathological Parameters.
Sorafenib Increases Tumor Hypoxia in Cervical Cancer Patients Treated With Radiation Therapy: Results of a Phase 1 Clinical Study.
Vascular Diseases
Double-Face of Vasohibin-1 for the Maintenance of Vascular Homeostasis and Healthy Longevity.
Vasculitis
Suppression of coronary vasculitis in a murine model of Kawasaki disease using an angiogenesis inhibitor.
Venous Thromboembolism
Potentiation of anti-angiogenic activity of heparin by blocking the ATIII-interacting pentasaccharide unit and increasing net anionic charge.
Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.
Virus Diseases
BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection-Implications for Oncolytic Viral Therapy.
Wilms Tumor
Integration of Myeloblastosis Associated Virus proviral sequences occurs in the vicinity of genes encoding signaling proteins and regulators of cell proliferation.
Suppression of tumorigenicity of rhabdoid tumor derived G401 cells by the multivalent HB-19 pseudopeptide that targets surface nucleolin.